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ABSTRACT 
Multiple sclerosis (MS) is a multifocal demyelinating disease with progressive 
neurodegeneration caused by an autoimmune response to self-antigens in a 
genetically susceptible individual. Current first-line disease-modifying therapies for 
MS decrease the risk for exacerbations, the changes on magnetic resonance 
imaging (MRI), and the disability. In addition to the immunomodulatory therapies 
approved for MS, monoclonal antibodies (mAbs) have emerged as promising 
treatments to reduce the symptoms of MS. In particular, natalizumab (tysabri, 
Biogen Idec), binding the α4-integrin molecules on T-cells and preventing their 
entry into the brain and the consequent inflammation, reduces relapse frequency, 
delays the onset of disease progression and improves disease outcome in the 
relapsing remitting form (RR) of MS. However, it has been associated with 
Progressive Multifocal Leukoencephalopathy (PML), an opportunistic and often 
fatal demyelinating disease of the white matter of the human brain, caused by the 
human polyomavirus JC (JCV) lytic infection of oligodendrocytes. 
By October 2012, a total of 298 cases of PML have been reported for 108,300 
natalizumab-treated MS patients. Sixty-three out of 298 died, representing a 
mortality rate of 21,1%. Longer duration of natalizumab treatment, the use of 
immunosuppressants before the initiation of natalizumab therapy, and positive 
status with respect to anti-JCV antibodies, assessed with the use of a two-step 
anti-JC virus antibody assay (STRATIFY JCV, Focus Diagnostics) have been 
identified as risk factors for PML. 
To better understand the molecular basis of demyelination, and to identify possible 
risk factors for the development of opportunistic infections and possible early 
prognostic markers of infectious complication during natalizumab treatment, an 
extensive longitudinal study has been performed, involving three different 
demyelinating diseases: MS, PML and Not Determined LeukoEncephalopathy 
(NDLE). The last one is a PML-like leukoencephalopathy, which occurs in HIV-1 
positive subjects, but without evidences of JCV replication in the Central Nervous 
System (CNS). Biological fluids from 76 MS patients subjected to monthly 
natalizumab infusions or to other treatment, enrolled as controls, and from 28 PML 
and 22 NDLE patients have been collected at various stages of the diseases. JCV 
genome was searched and quantified by means of quantitative Real-Time PCR (Q-
PCR), and molecularly characterized in order to monitor the viral presence and 
load, and to determine whether the viral organization may represent a risk factor for 
PML development. 
The results obtained from these analyses showed that no JCV DNA has been 
amplified in the CSF from NDLE patients. On the contrary, JCV load and the 
molecular organization of the viral transcriptional control region (TCR) amplified in 
the CSF seem to represent the main markers of prognosis in HIV-1-related PML. 
An increased JCV urinary shedding was detected in the group of MS patients 
treated with natalizumab, compared to control group (p< 0.05). In particular, this 
increased JCV excretion was present up to the 24th natalizumab infusion, whereas 
a decrease occurred after the 36th infusion. Although JCV reactivation detected in 
urine from MS patients had a subclinical nature, it cannot be ignored and the 
constant molecular monitoring of urinary JCV DNA allows to identify patients who 
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harbor the virus and verifying whether viral replication/shedding in the urine is 
really influenced by the treatment with the drug. In addition, the anti-JCV antibodies 
test performed on natalizumab-treated MS patients showed a false negative rate of 
7.9%, if compared with the results of JCV DNA test. Thus, testing JCV DNA, 
togheter with anti-JCV antibodies, represents a tool for PML risk stratification, also 
among patients who resulted negative at anti-JCV antibodies test, and may allow 
the identification of a specific, sensitive, reliable, reproducible and non-invasive 
biological marker of PML risk. 
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SOMMARIO 
La sclerosi multipla (SM) è una patologia demielinizzante caratterizzata da neuro-
degenerazione progressiva e causata da una risposta autoimmunitaria diretta 
contro auto-antigeni dell’organismo che si manifesta in soggetti geneticamente 
predisposti. Le terapie ad oggi disponibili riducono la severità e l’incidenza degli 
attacchi, così da prevenire le ricadute e prevenire o ritardare la progressione della 
malattia. Recentemente, in aggiunta alle terapie immunomodulanti basate sulla 
somministrazione di Interferone-β, Glatimer Acetato o Mitoxantrone, è stato 
introdotto il farmaco natalizumab (Tysabri, Biogen Idec), un anticorpo monoclonale 
umanizzato diretto contro l’integrina α4β1 (o VLA-4), che agisce impedendo 
l’adesione e l’extravasazione linfocitaria dal letto vascolare alla sede di 
infiammazione e, di conseguenza, previene i sintomi tipici della malattia e 
l’aggravamento della disabilità nei soggetti affetti dalla forma recidivante-remittente 
di SM. E’ stata identificata, tuttavia, un’associazione tra trattamento con 
natalizumab e insorgenza di Leucoencefalopatia Multifocale Progressiva (PML), 
una patologia opportunistica e demielinizzante della sostanza bianca cerebrale, 
spesso fatale. Tale patologia è causata dalla riattivazione, in condizioni di 
immunodepressione,  del polyomavirus umano JC (JCV) dal suo stato di latenza, 
con conseguente infezione litica e distruzione degli oligodendrociti. 
Al mese di Ottobre 2012 sono stati riportati 298 casi di PML su 108,300 soggetti 
affetti da SM e trattati con natalizumab, con un tasso di mortalità del 21.1% (63/298 
soggetti con PML sono deceduti). Tre fattori, singolarmente o in combinazione, 
sono stati associati a distinti livelli di rischio di sviluppare PML: positività agli 
anticorpi contro JCV, precedente uso di farmaci immunosoppressori e lunga durata 
del trattamento con natalizumab (> di 24 mesi). 
Al fine di comprendere le basi molecolari della demielinizzazione e di identificare 
possibili fattori di rischio per l’insorgenza di patologie opportunistiche e possibili 
marker di diagnosi precoce di PML nei soggetti trattati con natalizumab, è stato 
condotto un ampio studio longitudinale, riguardante tre differenti patologie 
demielinizzanti: SM, PML e LeucoEncefalopatia Non Determinata (NDLE). 
Quest’ultima patologia, a eziologia non ancora definita, è caratterizzata da lesioni 
simili a quelle associate a PML, insorge in soggetti HIV-1 positivi ed è 
caratterizzata dall’assenza del genoma di JCV  e di altri virus neurotropi a livello 
del liquido cerebro-spinale (CSF). 
76 soggetti affetti da SM e trattati con natalizumab o con terapia convenzionale di 
prima linea (questi ultimi arruolati come controlli), 28 soggetti affetti da PML e 22 
affetti da NDLE sono stati arruolati nello studio e campioni biologici di CSF, 
sangue, siero ed urine sono stati prelevati a diversi momenti della malattia. Il 
genoma di JCV è stato ricercato in tutti i campioni biologici raccolti tramite Real-
Time PCR quantitativa (Q-PCR) e, quando amplificato, è stato sottoposto a 
caratterizzazione molecolare, al fine di determinare se l’organizzazione genomica 
virale potesse rappresentare un fattore di rischio per lo sviluppo di PML. 
I risultati ottenuti hanno mostrato l’assenza del genoma di JCV nel CSF prelevato 
dai soggetti affetti da NDLE. Al contrario, la carica virale e l’organizzazione 
molecolare della regione di controllo trascrizionale virale (TCR) amplificata nel CSF 
dei soggetti affetti da PML sembrano rappresentare importanti fattori di prognosi. 
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Relativamente all’analisi sui soggetti affetti da SM, è emerso un aumento 
dell’escrezione urinaria di JCV nel gruppo dei pazienti trattati con natalizumab, 
rispetto al gruppo di controllo (p<0.05). In particolare, questo aumento si verifica 
fino alla 24a infusione mensile di natalizumab, mentre, a partire dalla 36a infusione, 
l’escrezione di JCV diminuisce fino a livelli pre-infusione. 
Nonostante la riattivazione di JCV nelle urine si sia dimostrata subclinica, 
l’aumento della prevalenza del virus nei soggetti trattati con natalizumab non può 
essere trascurato e il monitoraggio costante dell’eventuale presenza di JCV nelle 
urine di tali pazienti potrebbe permettere l’identificazione dei soggetti infettati dal 
virus e di verificare se la replicazione virale e l’escrezione nelle urine possano 
essere influenzate dal trattamento con l’anticorpo monoclonale. Inoltre, 
confrontando i risultati del test anticorpale contro JCV, a cui tutti i pazienti sono 
routinariamente sottoposti, con i risultati ottenuti attraverso l’analisi molecolare, è 
stato possibile verificare come il primo test sia affetto da una percentuale di errore 
(falsi-negativi) del 7.9%. Risulta, quindi, fondamentale affiancare sempre la ricerca 
del genoma virale nei fluidi biologici del paziente nel tempo al test per la ricerca 
degli anticorpi anti-JCV, al fine di identificare i pazienti a rischio PML, anche tra 
coloro i quali hanno mostrato negatività al test anticorpale, e di trovare un marker 
biologico specifico, sensibile, riproducibile e facilmente determinabile in modo non 
invasivo di rischio di PML.  
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1.1 Demyelinating Diseases 
Demyelinating diseases represent a heterogeneous group of diseases, which have 
in common the progressive loss of myelin from the nervous system. Since the 
myelin sheath of nerves is necessary for the conduction of neural impulses, this 
loss of myelin leads to an assortment of neurological symptoms that depend on the 
locations of the demyelinating lesions and may lead to disability and death. 
Important demyelinating diseases, affecting chiefly young adults, are 
immunomediated. The most common of these diseases is multiple sclerosis, an 
acquired disease of unknown etiology. 
A second type of demyelinating disease is caused by viruses. 
Finally, among hereditary neurodegenerative disorders, there are several 
categories of diseases due to the genetic lack of a particular metabolic enzyme 
causing a toxic build-up of chemical intermediates or a failure of myelin to form 
properly during development (dysmyelination). 
1.1.1 Multiple Sclerosis 
Over 160 years ago Charcot, Carswell, Cruveilhier and others first described 
clinical and pathological hallmarks of multiple sclerosis (MS), a multifocal chronic 
inflammatory demyelinating disease of the central nervous system (CNS) that 
leads to significant disability if left untreated. 
1.1.1.1 Clinical Course  
People with MS can typically experience one of four different disease courses, 
each of which might be mild, moderate, or severe (fig. 1). 
Relapsing remitting (RR) MS is the most common type of MS, affecting around 
85% of MS patients, and typically beginning in the second or third decade of life 
with a female predominance of approximately 2:1. It assumes that symptoms 
appear (a relapse), and then fade away, either partially or completely (remitting). A 
relapse is defined by the appearance of new symptoms, or the return of old 
symptoms, for a period of 24 hours or more, in the absence of a change in core 
body temperature or infections. In relapses, which can vary from mild to severe, 
symptoms usually come on over a short period of time, over hours or days, and 
they often stay for a number of weeks, usually four to six. The relapse, also known 
as attack or exacerbation, is followed by partial or complete recovery periods 
(remissions), during which no disease progression occurs [1,2]. 
Following an initial period of RR-MS, many people develop a secondary-
progressive (SP) disease course characterized by a worsening of the disability, 
with or without occasional flare-ups, minor recoveries (remissions), or plateaus. 
Before the disease-modifying medications became available, approximately 50% of 
people with RR-MS developed this form of the disease within 10 years after the 
time of the diagnosis [3]. 
The primary progressive form (PP), usually diagnosed in people in their forties or 
fifties, is characterized by slowly worsening neurologic function from the beginning, 
with no distinct relapsing or remission. The rate of progression may vary over time, 
with occasional plateaus and temporary minor improvements [3]. 
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The progressive relapsing (PR) is a relatively rare course of MS (5%), in which 
people experience steadily worsening disease from the beginning without 
remissions, but with clear attacks of worsening neurologic function along the way 
[3].  
Finally, patients having a single bout of disease but not yet diagnosed with MS are 
referred to as clinically isolated syndromes (CIS), which is considered the first 
manifestation of the disease [4]. 
 
 
 
 
 
Fig. 1: the four different MS clinical courses. 
 
 
1.1.1.2 Diagnosis 
MS diagnosis is based on establish clinical and, when necessary, laboratory 
criteria. Magnetic resonance imaging (MRI) is particularly valuable in supporting 
the diagnosis. It shows the typical MS plaques in periventricular white matter, 
cerebellum, brain stem, spinal cord and also plaques as small as 3 to 4 mm. 
Moreover, using contras material, MRI identifies acute plaques and is useful in 
monitoring therapeutic efficacy. MS plaques are hypointense (black holes) on T1-
weighted images [5]. 
Magnetic resonance spectroscopy (MRS) is helpul in demonstrating axonal injury. 
By measuring the concentration of N-acetyl aspartate (NAA), a neuron-specific 
marker, MRS monitors axonal dysfunction, which correlates with clinical disability. 
NAA levels are decreased in acute and chronic plaques. A temporary decrease in 
acute plaques is associated with reversible neurologic deficits. An increase in 
choline, a cellular membrane marker, is indicative of myelin breakdown [5]. 
Visual, somatosensory, and brainstem evoked potentials demonstrate a delay or a 
block in the conduction of nervous impulses and detected clinically silent plaques.  
Cerebrospinal fluid (CSF) analysis often shows an increase in γ-globulin fraction 
and the presence of oligoclonal bands (OCB). OCB arise from the intrathecal 
production of clonal IgG, by clonally expanded B-cells also located in brain 
parenchyma, and are present in more than 95% of MS patients [5,6]. 
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However, the definite diagnosis of MS is based on: (a) two or more episodes of 
neurologic deficits separated in time by at least 1 month, (b) two or more 
noncontiguous anatomic lesions on MRI, and (c) the absence of an alternative 
clinical diagnoses [5]. 
1.1.1.3 Epidemiological Features 
The prevalence of MS varies considerably around the world. The prevalence is 
highest in northern Europe, southern Australia, and the middle part of North 
America [7].  Between 50 and 100 per 100,000 Caucasians (lower in the other 
ethnic groups) are afflicted with this disease, and women are afflicted more than 
men at a ratio of about 2:1 (fig. 2) [8]. In Italy, about 61,000 individuals are afflicted 
with MS, equal to 1 case per 1,050 inhabitant and 1,800 new diagnosed cases per 
year. The onset usually occurs between the ages of 15 and 50 with the greater 
incidence between 20 and 30 years [9]. 
 
 
 
 
Fig. 2: prevalence of MS around the word for 100,000. 
 
 
1.1.1.4 Etiology and risk factors 
The etiology of MS remains elusive despite decades of research and a great 
interest in the disease. Three main hypotheses have been proposed: autoimmunity 
against the CNS, an infectious etiology, and a primary degenerative process 
affecting oligodendrocytes. These hypotheses are not mutually exclusive, as a 
primary viral infection can trigger autoimmunity or cause degeneration [10]. 
Evidence that genetic factors are at play in MS is unequivocal, but it is assumed 
that both the genetic background and environmental factors contribute to the 
disease manifestation. The high concordance rate of MS among monozygotic twins 
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(>25%), that is approximately six times the rate among dizygotic twins (5%), and 
the increased incidence in siblings of MS patients (2%) support some genetic 
factors [11]. 
During the last two decades, several investigative groups have collaborated to 
identify the individual genes that confer susceptibility to MS. The HLA class II 
extended haplotype HLA-DRB5*0101, HLA-DRB1*1501, HLA-DQA1*0102, and 
HLA-DQB1*0602 accounts for about 50% of the genetic risk of MS [12]. The whole 
genome scan effort has identified genes outside the HLA region as solid 
candidates for MS genetic risk. Single-nucleotide polyomophisms in the interleukin 
(IL)-2 and IL-7 receptors (IL-2, IL-7R) have been recently found to be associated 
with an increased risk for MS [13]. These allelic associations support an 
autoimmunity etiology in MS, as these alleles serve immune functions such as 
antigen presentation (HLA-DR), helper and regulatory T-cells functions (IL-2R), and 
memory T-cell (IL-7R). Some studies have reported immune deviation in MS, 
including cytokines imbalance in favor of a proinflammatory phenotype, deficiency 
in regulatory T-cells (Treg), and B-cells overactivity in the CNS reflected by the 
presence of increased IgG synthesis and oligoclonal bands in the CSF [10]. 
Potential environmental causes of MS, including behavioral and lifestyle as well as 
infectious agents, have been proposed in the etiology of MS. 
A role for infectious agents (bacterial and viral) is supported by epidemiological 
studies. The equatorial region of the earth is a low risk area for MS and the risk 
increases as you move farther north or south from the equator. In this situation, 
infectious agents present in these areas may play a role. Indeed, migration studies 
suggested that, if migration from an area of high MS risk to an area of low MS risk 
or vice versa occurred prior to 15 years of age, then the migrant acquired the risk 
of the area to which he moved; whereas, if migration occurred after 15 years of 
age, then the migrant maintained the risk of area from which he moved [reviewed 
in 8,14]. 
Viruses have long been thought to play a role in the etiology and pathogenesis of 
MS. Studies in favor of viral involvement include the observation that isolated 
populations which had no reported cases of MS experienced epidemics of MS after 
contact with North Americans or Europeans [14,15] and, secondly, that CD8+ T-
cells, cleaner of viral infections, were in the cellular infiltrate of active MS lesions. 
Moreover, exacerbation of MS can be correlated with viral infections, and, lastly, 
antibodies against various viruses and/or the viruses themselves have been 
directly isolated from MS patients [reviewed in 8]. 
Viruses that seem most associated with MS include rabies virus, herpes simplex 
virus (types 1 and 2), parainfluenza virus (type 1), measles virus, coronavirus, 
human T-cell lymphotrophic virus (type 1), and human herpes virus 6, all replicating 
extensively within the CNS [reviewed in 8]. 
The possible mechanisms by which viral infections could induce autoimmunity 
reactions that result in CNS inflammatory diseases are the molecular mimicry and 
the bystander activation. Molecular mimicry occurs when viral antigens have either 
sequential or structural similarities to self-antigens. So, viruses that encode 
molecular mimic could induce autoimmunity through either direct infection of the 
CNS or by peripheral infection. Instead, bystander activation is the nonspecific 
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activation of autoreactive cells due to inflammatory events caused by infection (fig. 
3). 
Among non-infectious risk factors, a protective effect of vitamin D in MS was 
recognized. This effect, in particular, is supported by the reduced risk associated 
with sun exposure and use of vitamin D supplements. Levels of 25-hydroxyvitamin 
D and 1,25-dihydroxyvitamin D were significantly lower in RR-MS patients than in 
controls or patients with PP-MS  [16]. Levels are also lower during relapse than 
during remission. These observations may be explained by the immunological 
effects of vitamin D, which include inhibition of myelin basic protein (MBP)-specific 
T-cell proliferation, enhanced differentiation of Tregs, and inhibition of IL-6 and IL-7 
secreting cells [16]. 
 
 
     
 
Fig. 3: mechanisms of viral induced autoimmunity. (A) bystander activation, (B) 
molecular mimicry. 
 
 
1.1.1.5 Pathological features 
The pathologic hallmark of MS consists of areas of focal demyelination, known as 
plaques, characterized by variable gliosis, inflammation and relative axonal 
preservation. The location, number, size, and shape of these lesions vary greatly 
among MS patients. They are disseminated throughout the CNS with a predilection 
for optic nerves, subpial spinal cord, brainstem, cerebellum, and periventricular 
white matter regions [17], but may also be found within grey matter, such as the 
cerebral cortex, thalamus, and basal ganglia. 
Early/acute plaques are poorly demarcated, soft (reflecting edema and tissue 
lysis), slightly granular, and white or pinkish yellow. Long-standing chronic plaques 
are distinctly demarcated, firm, slightly retracted (reflecting tissue loss), translucent 
or gelatinous, and have a brownish discoloration. 
MS lesions evolve differently during early versus chronic disease phases, and 
within each phase, different types and stages of demyelinating activity are evident. 
In the early stages of the disease, when patients present with clinical relapses and 
remissions, inflammatory demyelination leads to the formation of focal plaques. 
Instead, in later stages of the disease, chiefly in patients with SP or PP disease, 
additional pathology is seen, with a widespread demyelination in the cerebral and 
B A 
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cerebellar cortex as well as diffuse degenerative changes as in the white and in the 
grey matter [18]. 
Histologically, three basic processes characterize plaque formation: inflammation, 
myelin breakdown, and astrocytic fibrillary gliosis. 
Inflammation: inflammation occurs with vasogenic edema and perivascular 
infiltration with lymphocytes, chiefly major-hostocompatibility-complex (MHC) class 
I restricted CD8+ T-cells. MCH class II CD4+ T-cells as well as B-cells or plasma 
cells are seen mainly in perivascular spaces and in the meninges, whereas their 
infiltration into the compact tissue of the CNS is sparse. Active tissue injury in MS 
lesions is associated with activated microglia and infiltrated macrophages [19]. In 
MS lesions, irrespective their stage of development, the CD8+ T-cell population 
always predominates and shows clonal expansion, and two waves of T-cell 
infiltrates are seen in MS lesions in the course of lesion maturation. In lesions with 
initial oligodendrocytes injury, demyelination and tissue injury massive pro-
inflammatory microglia activation is present, associated with only a minor infiltration 
of T-cells, mainly MHC class I CD8+ cells. In addition, when myelin breakdown 
occurs and myelin debris are taken up by activated microglia and macrophages, a 
second wave of leukocytes infiltration, consisting predominantly of CD8+ cells but 
containing also CD4+ and B-cells, is seen [reviewed in 18]. 
Evidences suggest that the inflammatory response within the CNS may change 
with the progression of the disease. In particular, it decreases in severity with the 
age of the patients and disease duration, but active demyelination and 
neurodegeneration is invariably associated with inflammation, consisting of T-cells, 
B-cells, plasma cells and activated microglia and macrophages. At very late stage 
of the disease, inflammation may decrease to level seen in controls as the acute 
axonal injury [20]. 
Demyelination: the typical pathological feature of the sclerotic MS plaques is 
demyelination (fig. 4). Both the myelin sheath and the oligodendrocyte itself are 
destroyed within lesions, following attack by cells of the immune system that react 
with myelin-related epitopes, such as MBP. Immune attack involves both cellular 
immunity, with T-cells directed at myelin and oligodendrocytes and inciting 
phagocytosis by macrophages, and humoral immunity, with the secretion of anti-
myelin antibodies from B-cells and subsequent fixation of complement and 
opsonization of the myelin sheath and the oligodendrocyte by macrophages. 
Multiple, well delineated, focal demyelinated lesions can be observed in the white 
matter of brains from MS patients, and these contain a high density of 
immunohistochemical markers for various immune cells, including different 
populations of T-cells, B-cells, macrophages and microglia, such as cytokines and 
chemokines. These immune cells are thought to have infiltrated the sclerotic 
plaque during the inflammatory episode that leads to demyelination. 
Demyelinated plaques can also be observed in the cortical and subcortical grey 
matter. 
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Fig. 4: demyelination: the pathologic hallmark in MS. 
 
 
The biochemical and cellular mechanisms by which activated immune cells may 
destroy myelin and oligodendrocytes are multiple. The most common are 
presented below: 
a. direct binding of T-cells to myelin epitopes can lead to activation of 
macrophages and to a subsequent attack of the myelin sheath leading to 
its phagocytosis; 
b. release of cytotoxic cytokines or soluble toxic mediators such as nitric 
oxide from T-cells or microglia/macrophages can lead to destruction of 
myelin and myelin-producing cells; 
c. antibodies directed against myelin epitopes released from infiltrating B-
cells in the inflammatory lesion can bind to myelin, initiating fixation of 
complement, binding of macrophages, opsonization and phagocytosis of 
myelin and oligodendrocytes; 
d. release of cytotoxic mediators from immune or glial cells, such as free 
radicals, which can cause oxidative stress, and glutamic acid, can create 
further tissue damage; 
e. initial non-fatal damage to oligodendrocytes may initiate activation of an 
apoptotic cascade, perhaps by activation of death ligands or receptors 
such as Fas, FasL or Trail, that will result in delayed oligodendrocyte 
death. These apoptotic proteins can be activated by tumor necrosis factor 
(TNF), released from pro-inflammatory T-cells in MS lesions, and have 
been demonstrated to promote oligodendrocyte cell death in vitro; 
f. injury to the myelin sheaths may render oligodendrocytes vulnerable to 
environmental toxins or viruses. 
On the basis of patterns of staining for different immunological and cytological 
markers of cell injury and death, four different patterns of oligodendrocyte cell 
death can be distinguished in early acute MS plaques recovered from early disease 
[21].  
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Pattern I is characterized by sharp macrophage lesion borders, variable T-cell 
inflammation and T-cell-mediated autoimmune demyelination, and often extensive 
ongoing remyelination. 
Pattern II is similar to pattern I, however, further distinguished by the precipitation 
of activated complement and IgG on degenerating myelin sheaths in active lesions, 
so it is a B-cell (antibody)-mediated autoimmune demyelination. 
Pattern III active MS lesions demonstrate ill-defined macrophage borders with 
perivascular myelin sparing, where complement deposition is absent, with evidence 
of oligodendrocyte apoptosis and limited remyelination. 
Lastly, pattern IV lesions contain extensive non-apoptotic oligodendrocyte 
degeneration in the peri-plaque white matter adjacent to the active lesion. 
The B-cell-mediated pathology was the most frequently seen, in 53% of cases. 
These four different processes may occur to a different extent in different phases of 
disease; they are homogenous within a given patient but heterogeneous in 
different patient groups [reviewed in 22,23].  
Astrocytic fibrillary gliosis: meanwhile, the astrocytes begin to proliferate and 
become round with homogenous eosinophilic cytoplasm and numerous fibrillary 
processes. As the plaques mature, the edema and the inflammation resolve, with a 
disappearance of macrophages. The astrocytes produce more fibers with 
consequently formation of a glial scar that fills the demyelinated plaque (astrocytic 
fibrillary gliosis) [5].  
Important alterations affect also axons and oligodendrocyte. In axonal changes, a 
variable number of nerve fibers are damaged, some reversibly and some 
permanently, by the inflammatory process and by the loss of myelin sheats. During 
acute inflammatory demyelination, axons are probably damaged by the release of 
toxic inflammatory and nonspecific immune mediators in the lesion, such as 
proteases, cytokines, excitotoxins, and free radicals [24]. 
Regarding the oligodendrocytes, their number within the plaques may be reduced 
or they may be totally absent. 
Within the plaques, the neurons may be unaffected, or they may show atrophy and 
some losses. 
Remyelination: following acute inflammatory episodes, the resolution of the 
inflammatory processes is probably an important factor contributing to the 
neurological recovery often observed following clinical relapses. Complete 
remyelination give rise to the so-called “shadow plaques”, which are a demarcated 
area with reduced myelin density and thin myelin sheaths.  
Although remyelination is generally incomplete and is characterized by thinner 
myelin sheaths and shorter internodal lengths than in the original myelin, older 
remyelinated plaques may show an almost normal myelin thickness, often 
indistinguishable from normal white matter [25].  
Because of active demyelination, depletion of mature oligodendrocytes, and early 
remyelination occur simultaneously within some early MS lesions, the inflammatory 
microenvironment may have both a destructive and reparative functions. In fact, it 
appears that this remyelination is, at least in part, due to the activity of immune 
cells infiltrating the lesion. Immune cells in MS lesions can release anti-
inflammatory cyrokines, such as IL-4, IL-10, and neurotrophic factors [26]. 
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More than 40% of chronic MS lesions demonstrate evidence for remyelination [27], 
and in approximately 20% of MS patients, remyelination is so extensive that almost 
all plaques are shadow plaques [28]. 
1.1.1.6 Types of plaque  
Staging of MS plaques: a classification scheme that attempts to distinguish 
demyelinating activity from inflammatory activity, and that might be present in the 
lesion even in the absence of ongoing active demyelination, relies on the structural 
profile and chemical composition of myelin degradation products within 
macrophages, in correlation to the expression of macrophage differentiation 
markers by immunocytochemistry [29]. 
Using this classification scheme, active MS lesions predominantly consist of 
reactive astrocytes intermixed with phagocytic macrophages and variable T-cells, 
both CD4+ and CD8+, B-cell, and plasma cell perivascular and parenchymal 
infiltrates. Early active MS lesions contain macrophages expressing myeloid-
related protein (MRP14) and 27E10, both distinct markers of macrophage 
activation and differentiation. Since degradation of minor myelin proteins occurs 
rapidly, within one to three days, early active MS lesions contain myelin 
degradation products immunoreactive for minor myelin proteins including myelin 
oligodendrocyte glycoprotein (MOG) and myelin-associated glycoprotein (MAG), 
which disappear within 2 days, whereas late active lesions contain major myelin 
proteins including MBP and proteolipid protein (PLP), which are larger, more 
abundand, hydrophobic, and persist for 6-8 days. Inactive, demyelinated lesions 
are infiltrated by macrophages that lack degradation products of both minor and 
major myelin proteins. However, they contain empty vacuoles, the result of 
accumulation of neutral lipid components of myelin that cannot be digested and 
that accumulate and persist in macrophages. These macrophages can persist for 
up to six months in inactive lesions. Early remyelinating lesions are notable for the 
presence of clusters of short, thin, irregularly organized myelin sheaths, and are 
infiltrated by numerous lymphocytes and macrophages. Instead, late remyelinated 
lesions show few macrophages, astrocytic gliosis, and axons surrounded by newly 
formed thin myelin sheaths [23]. 
Type of MS plaques: a simple practical and diagnostic approach to classify MS 
lesions is based on the presence, the distribution, and the immunoreactivity of 
myelin-laden macrophages within the demyelinated lesions. 
In the acute active demyelinated plaque, macrophages are distributed evenly 
throughout the lesion, and the majority contains both early and late myelin 
degradation products. These lesions are characterized by relative axonal 
preservation, variable loss of oligodendrocytes, and profound perivascular and 
parenchymal infiltrates composed mainly of T lymphocytes. Also, fewer B-cells and 
oligodendroglia are present in lesions.  
Chronic active plaques are demyelinated lesions with relative axonal preservation 
and typically have sharply defined margins, with macrophages immunoreactive for 
both early and late myelin degradation products accumulating at the radially 
expanding plaque edge and diminishing in the inactive plaque center. Smoldering 
demyelinated plaques are characterized by an inactive center surrounded by a rim 
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of activated macrophages and microglia, few of which contain myelin degradation 
products. 
Acute and chronic active plaques are more commonly found in fulminant or early 
MS, or in SP-MS patients still experiencing ongoing clinical exacerbations, whereas 
smoldering and inactive plaques predominate in patients with chronic progressive 
disease [30]. 
1.1.1.7 Pathogenesis  
The hypothesis that MS is an autoimmune disease comes from the observation of 
similarities between MS and the animal model of the disease, experimental 
autoimmune encephalomyelitis (EAE). EAE is obtained by immunizing animals with 
myelin-derived proteins or peptides, such as PLP, MOG, MBP, and the disease is 
largely driven by myelin-specific CD4+ T-cells. 
The inflammatory cascade associated to MS is tought to be mediated by a a 
coordinated attack by T-cells, monocytes, and B-cells against CNS tissue (fig. 5). 
 
 
 
 
 
Fig. 5: pathogenesis of MS (from [31]). 
 
 
Peripheral T-cell activation: myelin-specific autoreactive T-cells found in MS 
patients are in an “activated state”, which is associated with an up-regulation of 
adhesion molecules that make these cells more prone to interact with the Blood 
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Brain Barrier (BBB) and drive an inflammatory response directed against myelin 
antigens within the CNS. How these autoreactive T-cells from MS patients became 
activated in the periphery is still a matter of debate, and processes such as 
molecular mimicry, wherein T-cells generated against non-self epitopes, as viral or 
microbial agents, cross-react with self-myelin epitopes of similar sequence, or T-
cell activation triggered by myelin antigens constitutively presented in cervical 
lymph nodes have been proposed as potential mechanisms [32-35]. 
T-cell migration into the CNS: After their activation in the periphery, autoreactive T-
cells and activated monocytes must access and bind to the BBB. Initial steps in the 
migration through the BBB involve interaction between adhesion molecules 
expressed on the endothelial cells and immune cells. Two lymphocyte adhesion 
molecules and their binding partners have been implicated in the extravasation. 
The α4β1 integrin (VLA-4, very late activation antigen-4) and lymphocyte function-
associated antigen (LFA-1), and their vascular and intercellular cell adhesion 
molecules, vascular cell adhesion molecule 1 (VCAM-1) and intracellular adhesion 
molecule 1 (ICAM-1), respectively, are all upregulated in vessels associated with 
MS lesions. Interestingly, there is a greater upregulation of VLA-4 and VCAM-1 in 
vessels of chronic lesions than in vessels of acute lesions, where LFA-1 and ICAM-
1 were high in both, suggesting a possible switch to their preferential use in late 
stages of lesion development [36]. 
The crossing of the BBB by activated immune cells relies on degradation of the 
basement membrane underlying endothelial cells by metalloproteinases (MMPs), 
which are produced by a variety of cell types, including monocytes, macrophages, 
T-cells and endothelial cells. They are also made by cells of the CNS, such as 
microglia, astrocytes, and oligodendrocytes, and are used for remodeling and 
repair of cell matrix component. Chemokines are also involved in the migration of 
immune cells across the BBB, regulating the recruitment and the migration of these 
cells. Chemokines displayed at the endothelial lumen bind chemokine receptors 
expressed on circulating leukocytes and determine which leukocytes subsets will 
extravasate and enter the CNS [4]. 
Inside the CNS: the oligodendrocyte/myelin attack: activated T-cells specific for 
one or more self antigens migrate into the CNS, through the disruption of BBB. 
This process is followed by an amplification of the immune response after the 
recognition of target antigens on antigen-presenting cells (APC). In particular, 
within the CNS, myelin-specific CD4+ T-cells are reactivated in situ by myelin 
antigens presented in the context of HLA class II molecules in conjunction with 
other molecules on the surface of APC (as macrophages or microglia). This 
reactivation determines the release of pro-inflammatory cytokines and other soluble 
mediators that will further disrupt the BBB and stimulate chemotaxis, resulting in a 
second wave of inflammatory cells recruitment into the CNS. The existence of T-
cells that are reactive to several self myelin and non-myelin antigens, including 
MBP, MAG, MOG, PLP, αβ-cristallin, phosphodiesterases, and S-100 protein, has 
been proposed [37-39]. Other amplification factors, including autoantibodies, are 
necessary to produce the demyelinated plaque [40,41]. 
Antibodies against antigens located on the surface of myelin sheath or 
oligodendrocyte can cause demyelination directly, through the activation of the 
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complement, leading to complement-mediated cytolisis. The antibodies may enter 
the CNS through the disruption of the BBB as a consequence of a T-cell initiated 
inflammatory response. Antibodies against both MOG and MBP can be found in 
patiens with MS and deposits of immunoglobulin and activated complement may 
be present in MS lesions, in which myelin is being degradated.    
Other factors, which may help degrade myelin and damage oligodendrocytes, 
include activated macrophages and microglial cells, through the production of 
proinflammatory cytokines (such as TNFα and INFγ), the generation of reactive 
oxygen or nitrogen species, the production of excitatory amino acids, the activation 
of complement component, or the releasing of proteolytic and lipolytic enzyme. 
Other factors potentially toxic for oligodendroglial cells include soluble T-cell 
products, the interaction of Fas antigen with Fas ligand, cytotoxicity mediated by 
the interaction of CD8+ T-cells with class I MHC antigens on antigen-presenting 
cells, and persistent viral infections [reviewed in 1]. 
1.1.1.8 Cellular players of the immune response 
CD4+ T-cells: following activation, naïve T-cells differentiate into different T-cell 
populations with various effector functions. Guided by cytokines produced by the 
dendritic cell (DC) that have been exposed to antigens, they differentiate into 
effector T helper cells (Th). T helper cells differentiation is initiated by signaling 
from DC to T-cells in the lymph node. Th1 cells, developed by INF-γ and IL-12 
action, produce pro-inflammatory cytokines, such as INF-γ, that activate 
macrophages to kill intracellular pathogens, and TNF-α. IL-4 promotes Th2 subset 
differentiation, which secrete IL-4 and IL-5. IL-23, produced by macrophages and 
DC, and IL-1β promote the development of Th17 cells, that synthesize the pro-
inflammatory cytokine IL-17A and IL-17F [42]. 
Th1 cells are believed to be further activated in the CNS by microglia, and 
subsequently they activate macrophages in the CNS to mediate myeline damage 
through Fc-R-mediated phagocytosis an the release of toxic mediators such as 
nitric oxide, proteases, free oxygen radicals, and TNF-α [43]. Th17 induces pro-
inflammatory cytokines and chemokines, enhances DC maturation, and promotes 
neutrophil function [44]. The percentage of Th17 cells is increased in the blood of 
MS patients with active disease, and Th17 are found in the perivascular 
inflammatory cuff in MS brains with acute and chronic active lesions, but not in 
inactive lesions [45]. The Th17 to Th1 ratio appears to be a critical determinant of 
CNS inflammation, and high Th17 to Th1 ratios are associated with T-cell 
infiltration and inflammation in the brain parenchyma [46]. 
Regulatory T-cells (CD4+CD25+ Treg) comprise a small subset of CD4+ T-cells 
that have also been implicated in MS pathogenesis, although the number of Treg 
cells in peripheral blood and CSF appears to be similar between MS patients and 
control group.  
CD8+ T-cells: Some evidences suggest that CD8+ T-cells have an important role in 
MS pathogenesis: 1) CD8+ T-cells are prominent in the inflammatory infiltrate in 
CNS lesions, and in some studies CD8+ T-cells outnumber CD4+ T-cells [47]; 2) 
infiltrating CD8+ T-cells are clonally expanded and may persist in the CSF for 
many years [48]; 3) CD8+ T-cells may promote CNS vascular permeability [49]; 4) 
adoptive transfer of activated myelin-specific CD8+ T-cells clones have been 
14 
 
shown to induce EAE, suggesting a key role for CD8+ T-cells in MS pathogenesis 
[50]; 5) axonal damage correlates with the number of CD8+ T lymphocytes 
infiltrating the lesion [51]; 6) CD8+ T-cells may participate in the axonal damage in 
MS by directly attacking neurons [52]. 
B-cells: B lymphocytes also play a key role in MS. This includes the presence of B-
cells, plasma cells, Ig, and complement deposition in the MS lesion in the majority 
of patients. In addition, autoantibody and complement-mediated myelin damage 
have been demonstrated in affected tissues. Different observations suggest the 
importance of B-cells in MS: 1) B-cells isolated from CSF and MS brain lesions are 
clonally expanded; 2) there is a intrathecal production of oligoclonal Ig in the CSF 
from MS patients; 3) B-cells may directly participate in the demyelinating process 
by secreting pathogenic antibodies that target oligodendrocyte with or without the 
presence of the complement; 4) B-cell responses, such as proliferation, antigen-
driven affinity maturation selection, and differentiation into antibody-producing 
plasma cells can be maintained locally within the CNS and may contribute to the 
pathogenic processes; 5) B-cells ablative therapy with the anti-CD20 monoclonal 
antibody rituximab, which depletes naïve and memory B-cells, was shown to 
reduce MS inflammatory brain lesions and clinical relapses [reviewed in 4].  
1.1.1.9 Treatment 
The treatment era for MS began in 1993, when the first disease-modifying therapy 
(DMT) was approved. This changed the focus of managing MS to the prevention of 
new disease activity. In fact, given the critical role of inflammation in MS, a key goal 
of MS therapy is the reduction or abolishment of related CNS inflammatory activity, 
with different therapies attempting to target different aspects of the aberrant 
immune response recognized to occur in MS. In addition to the known efficacy of 
anti-inflammatory therapies, the potential benefits of alternative strategies that may 
accomplish neuroprotection and/or remyelination in MS are recognized [53]. 
Currently there are eight different therapies for MS approved by the US Food and 
Drug Administration (FDA), and numerous new agents are being tested in clinical 
trials.  
Interferon-β (IFN-β) and glatiramer acetate (GA), the longest approved MS DMTs, 
are relatively safe and commonly used as first-line agents. While benefits have 
been demonstrated across the range of RR form of MS, unfortunately neither IFN-β 
nor GA have shown convincing efficacy in PP-MS. 
In 1993 IFN-β (with the commercial name Betaseron in the US, Betaferon in 
Europe) was the first DMT to be approved for the treatment of RR-MS, and 
additional IFN-β preparations have since become available for clinical use, IFN-β 
1a (Avonex and Rebif, respectively), and IFN- β 1b (as Extavia). Depending on the 
formulation, IFN- β is administered either subcutaneously or intramuscularly, and 
either on alternate days, three times per week, or once weekly. Adverse events of 
IFN- β include injection-site reactions, flulike symptoms, leukopenia, deranged liver 
enzymes, and depression. 
Although the exact mechanism of action is unknown, IFN-β drugs likely have 
multiple effects on the immune system [54]. The effects in the periphery include 
inhibition of antigen presentation, and at the BBB there is down-regulation of 
adhesion molecules and decreased production of matrix metalloproteinases. This 
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limits the T-cell activation and proliferation and the leukocyte migration across the 
BBB into the CNS. In addition, IFN-β determines apoptosis of autoreactive T-cells, 
modulation of cytokine production toward a more anti-inflammatory profile, and 
induction of regulatory T-cells [55]. IFN-β causes a shift from Th1 to Th2 cells, 
creating an anti-inflammatory milieu as an important mechanism in MS. However, 
more recently the effect of IFN-β on Th17 has been discovered to also be playing a 
role [56]. 
GA (Copaxone) is a random mixture of synthetic polypeptides composed of 4 
amino acids, alanine, glutamic acid, lysine, and tyrosine. In the context of MS, a 
number of potential immunological mechanisms have been discussed for GA, 
including the generation of suppressor cells, induction of tolerance, expansion of 
regulatory T-cell populations, alterations of APC, and neuroprotective autoimmunity 
[57,58]. Common adverse effects of GA (a once-daily subcutaneous injection) 
include local injection-site reactions, postinjection systemic reactions, and 
lipodystrophy (with long-term therapy). 
Other treatments, used as second line drugs, include mitoxantrone (Novantrone), 
fingolimod and oral cladribine. Mitoxantrone is a synthetic antineoplastic 
anthracenedione approved in 1987 as a treatment for acute myeloid leukemia and 
in 1996 for hormone-refractory prostate cancer [59]. It is a small molecule able to 
cross the BBB, where it interacts with the cells in the CNS, to inhibit DNA 
replication and DNA-dependent RNA synthesis as well as topoisomerase II ability 
to repair DNA. This ultimately leads to apoptosis of both proliferating and 
nonproliferating cells. Mitoxantrone has broad effects in MS resulting in 
suppression of T-cell, B-cell, and macrophage proliferation, decreased secretion of 
proinflammatory cytokines (IFN-γ, TNF, IL-2); enhanced T-cell-suppressor function, 
inhibition of B-cell function and antibody production, and inhibition of macrophage-
medicated myelin degradation. Mitoxantrone is given by intravenous infusion, as it 
is poorly absorbed orally. The efficacy of mitoxantrone in MS has been evaluated in 
four randomised controlled clinical trials. It was approved by the FDA in 2000 for 
worsening forms of MS including worsening RR-MS, SP-MS, and PP-MS. 
However, its use is limited by safety concerns. It is generally well-tolerated, 
although associated with nausea, urinary tract infections, menstrual disorders, 
amenorrhea, and mild alopecia when compared with placebo. 
Oral fingolimod was approved for the treatment of MS by the FDA and the 
European Medicines Agency (EMA) in 2010. Fingolimod is licensed for use as a 
first-line agent in the United States, but only as a second-line agent for active MS in 
Europe. Fingolimod, a synthetic analogue of the immunosoppressive fungal 
metabolite myriocin, is a sphingosin-1-phosphate (S1P) receptor modulator for 
once daily oral administration. In vivo, it is phosphorylated to yield the biologically 
active agent that binds to S1P receptors, modulating MS pathology, potentially 
acting both on the peripheral immune system and at central levels [60]. Fingolimod 
binding to S1P receptors on lymphocytes prevents their egress from lymph nodes, 
resulting in a dose-related reduction in the number of circulating lymphocytes and a 
reduced infiltration of autoaggressive lymphocytes into the CNS. Preclinical 
findings suggest that fingolimod may also promote neuroprotective and reparative 
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processes within the CNS through modulation of S1P receptors on neural cells. For 
these reasons, fingolimod is currently being investigated in PP-MS. 
Cladribine, an antilymphocytic drug, is an analog of the purine nucleoside 
adenosine [61,62], and induces apoptosis and depletion of both proliferating and 
quiescent lymphocytes, sustained depletion of CD4+ T-cells, less pronounced 
dose-dependent reductions in CD8+ T-cells, and smaller dose-dependent 
reductions in CD19+ and CD16+/CD56+ lymphocytes. As expected for a drug with 
preferentially lymphotoxic effects, myelosuppression is the major dose-limiting 
effect, and leukopenia, neutropenia and thrombocytopenia may occur. Cadribine 
was recently approved only in Australia and Russia as a treatment of RR-MS. 
1.1.1.9.1 New biological drugs 
As our understanding of the pathogenesis of MS has evolved, therapeutic 
strategies have been developed to target specific cells and processes that 
contribute to the myelin and axon damage characteristic of MS. In addition to the 
immunomodulatory therapies that have been approved for MS, monoclonal 
antibodies have emerged as promising treatments to reduce the symptoms of MS 
[reviewed in 63]. 
Monoclonal antibodies (mAbs) are a relatively new class of biologic agents that 
allow targeting of specific proteins on cell population and have shown promising in 
the treatment of a number of autoimmune diseases. Because they are designed to 
target specific antigens, mAbs may have more selective effects than drugs that 
potentially interact with multiple targets, although they still may have widespread 
effects on the immune system. By targeting specific antigens, mAbs potentially 
could provide improved efficacy compared with systemic immune-modulating 
therapies. MAbs approved or under investigation for MS include natalizumab 
(Tysabri), alemtuzumab (CamPath), rituximab (Rituxan) and daclizumab 
(Zenapax). 
The pathology of MS is thought to involve a cascade of immunologic processes 
involving T-cells, B-cells, macrophages, monocytes, DC, and an array of 
proinflammatory mediators and cytokines. Therefore, the modulation of these cells 
and their pathologic actions has been seen as a likely therapeutic target of the 
mAbs. 
1.1.1.9.2 Natalizumab 
Natalizumab (Tysabri [Biogen Idec, Zug, Switzerland and Elan, Athlone, Ireland]) is 
a humanized mAb that contains 90% human sequences and only 10% foreign 
sequences, represented by the amino acids from the mouse IgG in the variable 
regions that are needed to make the antigen binding site. 
It binds to the α4-integrin, a component of VLA-4 present on several leukocytes 
subtypes, in particular on T-cells. Binding of the antibody block the interaction with 
the ligand VCAM-1 on the surface of endothelial cells at the level of BBB, 
preventing the transmigration of leukocytes across the endothelium into inflamed 
parenchymal tissue [64] (fig. 6). In addition, some reports evidence that a long-term 
natalizumab therapy decreases the number of APC and the expression of MHC 
class II in cerebral perivascular spaces, which in turn may affect the reactivation of 
T effector cells in the CNS. 
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Fig. 6: natalizumab: mode of action. 
 
 
Alhough natalizumab has a biological half-life of 11 days, it is possible to detect in 
the CSF of natalizumab-trated patients, six months after the cessation of the 
therapy, few CD4+ T-cells, CD8+ T-cells, CD19+ B-cells, and CD138+ plasma 
cells, demonstring that natalizumab therapy may significantly impair 
immunosyrveillance in the brain and spinal cord. In addition, peripheral blood 
CD4+/ CD8+ ratio decreases significantly with increasing number of natalizumab 
doses, but remaines within normal limits. This may suggest that the differential 
effect of α4 integrin on cell numbers of CD4+ T-cells and CD8+ T-cells in 
peripheral blood may be a consequence of their activation and differentiation in 
secondary lymphoid organs [65]. 
Natalizumab was approved for the treatment of patients with MS who have the 
active RR form of the disease on the basis of its target mode of action and its 
positive effects on various clinical and MRI outcomes in the placebo-controlled 
clinical studies AFFIRM (Natalizumab Safety and Efficacy in Relapsing-Remitting 
MS), SENTINEL (Safety and Efficacy of Natalizumab in combination with Avonex 
[INFβ-1A] in Patients with Relapsing-Remitting MS), and GLANCE (Glatimer 
Acetate and Natalizumab Combination Evaluation) [reviewed in 66]. In particular, in 
the AFFIRM trial natalizumab was applied as a monotherapy in 942 MS patients 
who had not received any immunotherapy in the preceding 6 months. 96% of 
subjects in the treatment arm were devoid of new gadolinium-enhancing lesions 
compared to 68% in the placebo group. Relapse frequency was reduced by 
approximately two thirds over year one and two and natalizumab also significantly 
delayed disease progression [67]. The SENTINEL study tested the combination of 
natalizumab with IFNβ-1a once-weekly against IFNβ-1a alone. Individuals 
receiving combination therapy had a reduced relapse rate by 54% over IFNβ-1a 
alone and significantly fewer MRI lesions [68].  
Natalizumab is administered intravenously every 4 weeks and, in general, the 
treatment is well tolerated with infections, headache, fatigue, urinary tract 
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infections, arthralgia, and depression as the most common adverse effects in the 
monotherapy [67]. Based on the positive interim analysis of phase III AFFIRM and 
SENTINEL trials, natalizumab was approved by the FDA for the treatment of 
relapsing forms of MS in November 2004. 
Commercial and clinical trial dosing of natalizumab was suspended voluntarily in 
February, 2005, when two patients in the combination trial of natalizumab and 
IFNβ-1a developed Progressive Multifocal Leukoencephalopathy (PML) [69,70]. In 
addition, a third case of PML was diagnosed in a patient receiving natalizumab for 
the treatment of Crohn’s disease [71]. 
The incidence of PML was estimated to be approximately 1 case per 1000 MS 
patients treated with natalizumab. However, the drug was reintroduced in the USA 
and approved in the European Union in June, 2006, after no additional cases of 
PML were identified in previously treated individual. The FDA approved an 
application for resumed marketing of natalizumab as a monotherapy in patients 
with relapsing forms of MS who have not responded adequately to, or cannot 
tolerate other treatment. To minimize the risk of further serious adverse events and 
to continue the assessment of natalizumab safety profile in clinical practice, a 
special restricted distribution program and a risk management plan were 
developed, including the TOUCH (Tysabri Outreach Unified Commitment to Health) 
prescribing program, mandatory in the USA, and the TYGRIS (Tysabri Global 
Observation Program in Safety). In Europe, natalizumab has been approved by the 
EMEA as monotherapy for patients with high disease activity despite sufficient 
treatment with IFNβ as well as for patients with initially high disease activity. 
As of October 3, 2012 there have been 298 confirmed cases of PML among 
108,300 natalizumab-treated MS patients, with 63 deaths and a mortality rate of 
21.1%. 
As natalizumab and other biological drugs has a suppressive action on the immune 
system, this effect may increase the risk for opportunistic infections. Although the 
overall incidence of infections was low, in the monotherapy pivotal trial, certain 
types of infections were more common in patients treated with natalizumab than in 
placebo-treated patients (eg, pneumonias, urinary tract infections, gastroenteritis, 
vaginal infections, tooth infections, tonsillitis, and herpes infection). 
1.1.1.9.3 Other monoclonal antibody therapies 
Alemtuzumab (previously called Campath-1H; Campath in the US [Genzyme, 
Cambridge, MA, USA and Bayer Health Care Pharmaceuticals] and MabCampath 
in Europe [Genzyme and Bayer Schering Pharma AG, Berlin, Germany]) is a 
humanized mAb directed against the CD52 antigen, which is present on the cell 
surface of T and B lymphocytes, monocytes, macrophages and eosinophils but not 
stem cells. It might deplete these cells through complement mediated lysis, 
antibody-dependenT-cell toxicity and induction of apoptosis, and therapy with this 
mAb results in a long-term immunosuppression. Alemtuzumab is already licensed 
for the treatment of refractory chronic lymphocytic leukemia and is under 
investigation in the treatment of MS [72]. The results of the alemtuzumab studies in 
MS report generally consistent safety profiles, with the most prominent adverse 
effect being the development of Graves’ disease, an autoimmune hyperthyroidism. 
In addition, the profound lymphopenia associated with alemtuzumab administration 
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results in an increased incidence of infections (which have included cases of 
measles, spirochetal gingivitis, herpes zoster, varicella zoster, recurrent oral 
aphthous ulcers, and pyogenic granuloma) [73]. 
Daclizumab (Facet Biotech, Redwood City, CA, USA and Biogen Idec) is an IL-2 
receptor antagonist that specifically targets the binding site on the IL-2 receptor α 
chain, CD25. Because CD25 is present at low levels on resting T-cells, but exists 
at particularly high levels on activated T-cells, it is thought that selective targeting 
of CD25 will correlate with selective blocking of activated T-cells. Further, because 
T-lymphocyte activation is central to the inflammation characteristic of MS lesions, 
this blockade theoretically would reduce the inflammation in the brain associated 
with MS lesions [74-76]. 
Daclizumab is approved by the FDA for the treatment of renal transplant rejection 
and has been tested as a therapy for cardiac allograft rejection [77]. Daclizumab 
has been studied for the treatment of MS as adjunctive therapy in patients failing 
INF treatment.  
In the safety analysis, was found an increase in the number of infections during the 
daclizumab treatment phase, although they were all mild urinary and upper 
respiratory tract infections common in MS. Other analysis have seldom detected 
paresthesias, mild leukopenia without lymphopenia, mild anemia, rash, and 
transient low-level increase of liver enzymes [74,75]. 
Rituximab (Rituxan in the US [Genentech, San Francisco, CA, USA and Biogen 
Idec, Weston, MA, USA] and MabThera in the rest of the world [Roche, Basel, 
Switzerland]) is a chimeric mAb (murine variable regions fused onto human 
constant regions) against the CD20 antigen, which is present on pre-B-cells and B-
cells, but not on antibody-producing plasma cells or stem cells in the bone marrow. 
Administration of rituximab results in B-cell depletion with preservation of antibody 
production by plasma cells. B-cells number is restored in the peripheral circulation 
in approximately 3 to 12 months after treatment. 
Rituximab is approved by the FDA for treatment of B-cell lymphomas [78,79] and is 
under investigation as a therapy for a number of autoimmune diseases. There are 
several completed or ongoing investigations of rituximab as a treatment for MS 
[reviewed in 80]. Reduction in the number of B-cells and T-cells from the circulation 
and the CSF has been observed following rituximab treatment [reviewed in 80]. A 
recently published study has demonstrated the potential of rituximab as a very 
effective therapy for MS, with a marked reduction in new enhancing lesions 
maintained for 48 weeks. Clinically, these patients also had a significant reduction 
in relapses sustained over this time period [81]. 
Adverse effects of therapy, observed with the initial infusion and substantially less 
following the second mAb infusion, included chills, headaches, nausea, fever, 
fatigue, throat irritation, and pharyngeal pain. Potential rituximab-associated 
conditions include serum sickness and PML, which have been observed during 
therapy of other conditions, including systemic lupus erythematosus (SLE), but not 
in MS patients [82]. 
Since PP-MS has been refractory to most immunotherapies thus far, proving that 
rituximab can be effective for PP-MS would be a major advancement in MS 
therapeutics. 
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1.1.2 Progressive Multifocal leukoencephalopathy 
PML is a rare and often fatal demyelinating disease of the CNS that was first 
reported in 1958 by Astrom and colleagues [83], following the examination of brain 
tissue from two cases of chronic lymphocytic leukemia and one case of Hodgkin 
lymphoma. PML occurs as a devastating neurological opportunistic infection in the 
contest of severe impairment of the immune system, such as Acquired 
ImmunoDeficiency Syndrome (AIDS) or treatment with immunomodulatory 
compounds, mainly a number of mAb and it is caused by the Polyomavirus JC 
[84,85]. 
1.1.2.1 Epidemiology of PML 
Prior to the era of Human Immunodeficiency virus 1 (HIV-1), PML remained a 
relatively rare disease seen in few immunosuppressed patients, including 
individuals with hematological malignancies, organ transplant recipients and 
people with chronic inflammatory conditions, with an estimated incidence of 0.07% 
[86]. 
However, PML prevalence dramatically increased during the AIDS epidemic, where 
up to 5% of AIDS patients developed the disease. Mortality related to PML has also 
increased from 1.5 per ten million persons in the pre HIV era to 6.1 deaths per ten 
million persons in the post HIV era [87]. 
Since 1996 highly active antiretroviral therapy (HAART) became the standard 
practice for HIV treatment [88]). It has reduced the incidence of and mortality due 
to PML in patients infected with HIV-1. Before the use of combined antiretroviral 
therapy, PML affected 3–7% of HIV-1 positive patients and was the cause of up to 
18% of fatal CNS diseases. The incidence (rate of new cases) has decreased 
substantially with combined antiretroviral therapy, although not to the same extent 
as that of other opportunistic infections of the CNS [reviewed in 89]. In pre-HAART 
era the incidence of PML varied from 0.3% to 8%, but the wide use of antiretroviral 
treatments led to a significant reduction from 0.7 cases per 100 patient-years to 0.7 
cases per 1000/ person-years at risk [reviewed in 90]. 
Prior to HAART, AIDS-associated PML (AIDS-PML) was typically fatal within 6 
months from the diagnosis, but, with the use of antiretroviral therapy, survival 
among patients in this PML population has begun to improve, changing from 0-
30% 1 year after diagnosis to 38-62% since the introduction of HAART [88,91]. 
However, HIV infection is still the most commom immunodeficiency setting for 
PML, accounting for about 80% of cases, followed by hematologic malignancies 
(~8%), solid cancer (~3%), organ transplants and autoimmune disease treated with 
immunomodulators [92]. 
1.1.2.2 Neuropathology and image findings 
The central pathologic feature of PML is the infection of the oligodendrocytes with 
the polyomavirus JC (JCV), which leads to lysis of the cell. The infection spreads to 
surrounding oligodendrocytes and results in focal destruction of myelin; 
microscopic foci of myelin breakdown coalesce to form larger lesions, primarily in 
subcortical white matter and then evolving towards the deep periventricular 
regions, involving also thalamus and basal ganglia. Lesions are most commonly 
present in the cerebral hemispheres, but may also affect the cerebellum and the 
brain stem [93]. 
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PML may affect the gray matter, usually in association with white matter 
involvement [83,94]. The infected oligodendrocytes have inclusions of viral 
particles in the nuclei, which give the appearance of inclusion bodies and loss of 
chromatin structure upon examination by light microscopy. Oligodendrocytes are 
diminished in number and are principally located at the lesion’s periphery. The size 
of the nucleus may also enlarged by as much as 2- to 3-fold. The multifocal nature 
of the lesions suggests a hematogenous spread of the virus to the brain. 
To a lesser extent, astrocytes are also infected with JCV. These cells appear 
enlarged, with hyperchromatic, deformed and “bizarre” nuclei containing JCV 
particles; the nuclei appear irregular, lobulated and premitotic, but do not become 
neoplastic (fig. 7). 
Although neurons themselves are rarely productively infected by JCV, 
demyelination leads to axonal dysfunction, and the demyelinated axon is 
susceptible to injury by cellular products released by the glial cells. Axonal injury 
can result in a retrograde loss of the neuronal cell body. Loss of neurons is likely 
permanent. 
Conventional MRI shows an extensive involvement of subcortical white matter, with 
multifocal, bilateral, asymmetrical lesions in early stages of the disease, that 
appear hyperintense in T2-weighted sequences and hypointense in T1-weighted 
sequences (fig. 7). 
Invading macrophages are commonly seen in the centers of lesions. They act as 
scavengers and are actively involved in removal of myelin debris in the sites of 
lesions. Macrophages and microglia are not infected by JCV. 
Although there are no fundamental differences between the pathology of PML in 
patients with and without AIDS, several subtle differences have been identified. In 
AIDS-PML patients, there can be massive necrotic lesions with infiltration by HIV-
infected macrophages [95], and grey matter and infratentorial lesions are also more 
common than in non-AIDS-PML patients. 
However, the location of the lesions is generally similar in AIDS- and non-AIDS-
PML patients [97,98]. 
Lymphocytes are not typically seen in PML lesions except if there is restoration of 
the immune system leading to an Immune Recinstitution Inflammatory Syndrome  
(IRIS). Under these circumstances, CD8+ T-cells are the predominanT-cell type 
and are present in perivascular regions at sites distant from areas with JC virus 
infection as well as in focal collection in the parenchyma in proximity to JCV-
infected cells [99,100]. The presence of cyto-toxic T-cells against JCV is 
considered to be a good prognostic sign. It is postulated that the rapid restoration 
of the immune system may lead to an expansion of activated T-cells, which may 
contribute to the massive inflammatory response seen in patients with IRIS and 
can result in significant morbidity and mortality. 
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Fig. 7: histopathological features of PML: (A) MRI of the brain showing the 
characteristic hyper-intense areas located in the sub-cortical white matter; (B) 
extensive lytic lesions in the sub-cortical white matter; (C) extensive areas of 
myelin loss; (D) demyelinated areas highlighted with a special stain for myelin; (E) 
giant reactive astrocytes with bizarre atypical nuclei; (F) enlarged oligodendrocytes 
harboring intranuclear eosinophilic inclusion bodies; (G) immunohistochemistry for 
the JCV capsid protein VP-1 shows robust reactivity in the nuclei of infected 
oligodendrocytes, demonstrating productive infection; (H) the intranuclear inclusion 
bodies in oligodendrocytes are composed by numerous icosahedral viral particles 
as demonstrated by electron microscopy (from [96]). 
 
 
1.1.2.3 Clinical features 
Signs and symptoms: PML has a tumultuous course and a poor prognosis within 
few months [84,101]. The introduction of HAART has modified the HIV-related CNS 
disease scenario, and new form with different clinical presentation and better 
prognosis have been described [102]. The classical form of the disease have a 
multisymptomatic onset, with symptoms varying on the basis of the location and 
the size of lesions. However, the most frequent clinical presentation is 
characterized by motor deficits, altered consciousness, gait ataxia, and visual 
symptoms. Atypical presentations include pure cerebellar syndrome, reflecting a 
productive infection of granule cell neurons, meningitis, meningoencephalitis, 
progressive myoclonic ataxia, and muscle wasting associated to extrapyramidal 
signs [90,101,103].   
Diagnosting testing: diagnosis can be divided into three stages: clinical suspicion, 
radiological identification, and confirmation of cause by CSF or tissue analysis 
[104]. The first of these stages relies on the character and development of focal 
neurological symptoms and signs over time and disease susceptibility. 
The second stage in diagnosis involves the detection and characterization of brain 
lesions by MRI, which shows characteristic white-matter lesions in brain areas 
associated with the clinical deficits. Because the lesions involve demyelination, 
they are usually hyperintense on T2-weighted and FLAIR (Fluid-Attenuated 
Inversion Recovery) MRI sequences, but hypointense on T1-weighted sequences, 
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indicating white matter destruction. The hypointense lesions help distinguish PML 
from other pathologies, primarily HIV-1 encephalopathy, with more diffuse central 
white-matter changes that are not detected on T1 sequences [89]. 
Definitive diagnosis can only be made when PML is confirmed by histopathology, 
which must evidence a consistent neuropathology in the brain (biopsy or autopsy) 
with JCV DNA or protein detected by in situ techniques. 
The CSF-confirmed PML has a lower degree of diagnostic given the variation in 
sensitivity and specificity of Polymerase Chain Reaction (PCR) assays in different 
laboratories. The detection of JCV DNA in CSF by PCR had a sensitivity of 72-92% 
in the pre-HAART era, but fell to 58% after the introduction of HAART [105,106]. 
This is probably related to the better immune control of the virus and the higher 
CSF clearance of the virus by immune cells. 
The occurrence of PML in patients treated with novel immunomodulant therapies 
has stimulated the search for biological markers that are more easily accessible, 
reliable and detectable than CSF for the early phase of the disease [85,107,108]. 
So far, no blood biomarkers of JCV activity have been identified. 
1.1.2.4 Therapeutic options 
Classical treatment of PML: the prognosis of PML is generally poor. In the pre-
AIDS era and before antiretroviral drugs were available, death was nearly 
universal, with an average survival of 9 months in non-HIV patients and 2 to 4 
months in patients with HIV infection [103]. 
At present, there is no specific antiviral drug against JC virus, but a number of 
treatment options have been used for PML, largely without success. The main 
approach to treatment of HIV-1-related PML involves combined antiretroviral 
therapy with the objective of reversing the immunological defect that interferes with 
the normal host response to JCV. This is therefore an indirect approach to 
treatment, but it is the only one that has proven effective. 
In patients with both PML and HIV-1, combination antiretroviral therapy stops 
progression of leukoencephalopathy in about half of those who receive it [109]. 
Unfortunately, neurological deficits frequently persist because of irreparable loss of 
brain tissue, and only a few patients functionally improve.  
Other treatment options used for PML treatment, but without success, have 
targeted various point in viral cycle such as virus entry and replication, and 
includes cidofovir (CDV), cytosine arabinoside (Ara-C), chlorpromazine, and 
mefloquine [110]. Cidofovir, a nucleoside analog, inhibits viral replication for its 
inhibitory action on DNA polymerase, but its effect has been tested with 
contradictory results [111,112]. Chlorpromazine inhibits clathrin-dependent 
endocytosis, which is required for JCV infection [113]. This drug is effective in 
limiting JCV infection in human brain-derived cell cultures, but has serious side 
effects and toxicity issues. 
The antimalaric drug mefloquine was shown to inhibit JCV replication using in vitro 
cell culture models derived from human fetal brain in an attempt to identify drugs 
and biologically active molecules with antiviral activities against JCV [114]. 
Mefloquine has favorable pharmacokinetic properties and is known to cross the 
BBB and accumulate in the brain, where JCV infection is pathological, but has 
been associated with neurotoxicity [115]. Several independent case reports 
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showed that mefloquine treatment of PML was successful in reducing the viral 
burden in the brain and was associated with improvement of clinical symptoms 
[116]. However, as reported at the 2011 annual meeting of the American Academy 
of Neurology, a multicenter clinical trial supported by Biogen-IDEC Inc. and Elan 
Pharmaceuticals failed to show a reproducible reduction in the JCV DNA in PML 
patient CSF or reduced clinical progression of PML in response to mefloquine 
treatment [117]. 
However, the best treatment for PML is the restoration of the immune system, 
although even this is not ideal, since it can lead to IRIS. It is hence recommended 
that interventions made to restore the immune function, such as initiation of 
antiretroviral agents in HIV-infected individuals and removal of the offending 
chemotherapeutic agent, are made concomitantly to patients monitoring for the 
development of IRIS and treated with steroids accordingly [118]. 
Withdrawal from immunosuppressants in non-AIDS PML and HAART therapy in 
AIDS-related PML have been associated with immune reconstitution in the brain 
and control of viral replication. Rapid immune reconstitution is important to CNS 
immunosurveillance and control of JCV replication [reviewed in 119]; however, IRIS 
itself can be a serious, often fatal outcome. 
Low T-cell counts and high numbers of copies of JCV DNA in the CSF at the time 
of PML diagnosis are clear risk factors for death [reviewed in 119]. Early use of five 
drug combined antiretroviral therapy after PML prognosis has been shown to 
improve survival, which is associated with recovery of anti-JCV T-cell responses 
and reduction of JCV DNA in the CSF [120]. 
Future therapeutics for PML should focus not only on blocking viral replication but 
also on reconstituting an effective T-cell response against the virus in the brain. 
Treatment of PML occurring with newer biological agents: the fundamental step in 
treating confirmed or suspected PML in the setting of an offending agent is 
discontinuing the treatment and reversing the effect of the drug. In the case of 
Natalizumab treatment, 80% of binding sites remain occupied one month after 
administration and activity is still evident 3 months after discontinuation following 
two intravenous infusions separated by 4 weeks. Moreover, six months after 
cessation, an altered CD4/CD8 T-cell ratio in the CSF remains evident [reviewed in 
101]. 
So, it is definitively important to eliminate the antibody from the body as rapidly as 
possible; plasma exchange allows decreasing the concentration of Natalizumab in 
the blood and desaturated α4 integrin.  
1.1.2.5 Prognosis 
Although PML is still a fatal disease and there is currently no specific treatment, the 
advent of HAART has altered the clinical picture of the disease for HIV-positive 
PML patients. 
HIV-positive PML patients are living longer in the HAART era. Several studies have 
defined factors associated with PML prognosis in HIV positive patients. Clinically, a 
high CD4+ T-cell count, a low plasma HIV-1 RNA load, the presence of JCV 
cytotoxic T-cells, contrast enhancement on radiographic imaging and neurological 
recovery, and a low JCV load in CSF seem to be associated with longer term 
survival and with a good prognosis for PML patients [88,91,121,122]. In particular, 
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the amount of JCV viral load in CSF was inversely correlated to survival in a pilot 
study [123]. This was confirmed in a second study where a threshold of 50 to 100 
JCV genome copies/µl of CSF was significantly associated with mortality [124]. 
Prior to the advent of HAART less than 10% of the HIV-positive patients was alive 
one year after the time of PML diagnosis [93]. 
To date, clinical stabilization of PML is seen in 50% of patients, and a survival rate 
as high as 63% has been reported, although survivors are often left with severe 
neurological sequellae [125]. 
1.1.2.5 PML and IRIS 
Under treatment with HAART in HIV-positive patients with PML, the PML IRIS is 
commonly observed [126]. This disease condition is an inflammatory response to 
clinically apparent or subclinical pathogens, associated with recovery of the 
immune system after a period of immunosuppression, which leads to infiltration of 
lymphocytes into the PML lesions. An elevation of the CD8+ and CD4+ T-cell 
counts and the clinical appearance under treatment with HAART are used to 
diagnose PML-IRIS. 
In PML, IRIS happens in two settings. The first is when symptomatic disease is 
treated with HAART and inflammation develops in relation to the existing lesions 
(paradoxical IRIS) [127]. In this setting, distinguishing a favourable immune 
reconstitution associated with clinical stabilisation from harmful IRIS associated 
with clinical worsening is important [128]. 
The second setting is when patients develop PML after the start of HAART and an 
inflammatory picture is found on MRI (unmasking IRIS) [126]. 
In PML-IRIS patients the clinical picture often aggravates due to the emergence of 
increased inflammation in the CNS. Inflammation can also lead to mass effects 
with herniation. In such severe cases the application of steroids can be beneficial. 
PML-IRIS can lead to a prolonged survival and even a cure from PML, when 
adequately managed [129].  
1.1.2.6 PML and AIDS 
PML is the cause of death in 3 to 5% of AIDS patients [85]. The incidence of PML 
complicating HIV/AIDS is higher than that of any other immunosuppressive 
disorder relative to their frequencies. 
This may be due to several factors. First, the duration and extent of 
immunosuppression in HIV/AIDS may be greater compared with other 
immunosuppressive disorders [130]. Then, JCV specific CD4+ T-cell responses 
are impaired in HIV-infected patients with active PML compared to PML survivors 
on effective and prolonged antiretroviral therapy [131]. In addition, changes in 
cytokine secretion induced by HIV, viral interactions in coinfected cells, and 
increased BBB permeability facilitate the entry of B-lymphocytes infected with JCV 
into the brain [132]. Finally, there exist specific molecular mechanisms whereby 
HIV-1 may promote JCV gene expression, and participate in the pathogenesis of 
JCV [133]. 
The HIV-1 encoded regulatory protein Tat has been shown to increase 
transcription from JCV in glial cells by binding and enhance the JCV promoter 
[reviewed in 119], while the JCV agnoprotein may cause a slight decrease in the 
replication of HIV [134]. Tat protein mediates the activation of JCV early promoter 
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via a Tat-responsive transcriptional control element, named upTAR. Binding of Tar 
to upTar is mediated by the association of Tat with the cellular nucleic acid binding 
protein, Purα. Tat and Purα synergistically activate JCV late gene expression 
resulting in >100-fold induction [reviewed in 135]. 
Tat has also been shown to be secreted from HIV-1 infected cells and internalized 
by uninfected neighbouring cells, affecting cellular function [136]. 
Additionally, HIV infection increases permeability of the BBB [137]. The increased 
permeability may contribute to JCV crossing of the BBB in infected B-cells or as 
free virus. HIV proteins, such as Tat and Nef, can cause damage to astrocytes 
[138], and direct infection of astrocytes by HIV may lead to neuronal damage [139]. 
This damage may lead to increased inflammation and further infiltration by JCV 
infected lymphocytes and may help facilitate onset of PML. 
1.1.2.7 PML and immunomodulatory treatments 
Treatment with mAbs is a unique, newly identified predisposing factor for the 
development of PML. These therapies are promising for the treatment of a number 
of autoimmune conditions and lymphoproliferative disorders. Among the mAbs that 
increase the risk of PML are natalizumab (Tysabri), a α4β1 and α4β7 antagonist, 
and efalizumab (Raptiva), an anti-CD11a antibody. 
Efalizumab is a humanized mAb against CD11a, a subunit of the leukocyte 
function-associated antigen type 1 (LFA-1), a T lymphocyte adhesion molecule, 
used in moderate to severe plaque psoriasis [140]. LFA-1 binds intercellular 
adhesion molecule 1 (ICAM-1), which allow migration of T lymphocytes from 
circulation into sites of inflammation. By binding the CD11a, efalizumab determined 
an alteration in apoptosis, cytotoxicity, cell proliferation, cytokine production, 
antigen presentation and gene activation [141]. This set of events affects psoriasis 
pathogenesis at multiple levels, in particular by inhibiting the initial T-cell activation 
in lymph nodes, preventing binding of T-cells to endothelial cells and blocking 
trafficking of T-cells from the circulation into the psoriatic skin preventing their 
reactivation in the dermal and epidermal layer [141]. 
Efalizumab was voluntarily withdrawal from the market in the spring of 2009 
because of the occurrence of PML at incidence of approximately 1:500. 
Rituximab has demonstrating efficacy in treating lymphoproliferative and a wide 
variety of autoimmune diseases, especially rheumatoid arthritis, SLE and MS 
[81,142,143]. 
In addition, PML cases have been observed after treatment with the small 
molecules mycophenolate mofetil, cyclophosphamide, fludaribine and azathioprine 
[85]. 
Mycophenolate mofetil is a selective, non-competitive and reversible inhibitor of 
inosine-5’-monophosphate (IMP) dehydrogenase, approved to prevent rejection of 
renal, cardiac and liver transplant. It has also demonstrated efficacy in the 
treatment of some autoimmune diseases, including SLE, autoimmune glomerular 
disease and myasthenia gravis. The molecule is metabolized by the liver to 
become mycophenolic acid, which blocks B and T-cell proliferation by inhibiting 
IMP dehydrogenase and preventing purine synthesis. The mechanism by which 
mycophenolate mofetil increase the risk of PML is unclear, but probably it is related 
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to its activity of T-cells depletion and lowering the immunological barrier for the 
disease by reducing or eliminating JCV cytotoxic T lymphocytes.  
Ultimately, it can be stated that the occurrence of PML in relationship with 
compounds that limit the access of T-lymphocytes to the CNS underlines the 
importance of the celluklar component of the immune system in the control of JCV 
replication within the brain. Moreover, the occurrence of the pathology in the 
context of B-lymphocytes depletion suggests that B-cells are not the principal 
vehicle for JCV to enter the brain, and that humoral immunity might play a role in 
the control of JCV replication. On the other hand, B-cell depletion may impact on T-
cell activity, which is known to be important in the control of JCV replication, and 
may stimulate the proliferation and the redistribution of the infected pre-B 
lymphocytes from the bone marrow to the bloodstream, favouring the viral entry 
into the CNS [144]. 
1.1.3 Not Determined LeukoEncephalopathy 
After the introduction of HAART in the treatment of HIV-infected patients, the 
frequency of PML was not reduced as opposed to other opportunistic infections 
and, in addition, an increase in the occurrence of other form of HIV-related 
leukoencephalopathy has been reported. A PML-like leukoencephalopathy, 
indicated as Not Determined LeukoEncephalopathy (NDLE) is characterized by 
intense perivascular macrophage infiltration, extensive demyelination, and 
evidence of very high levels of HIV replication in the brain, in the absence of the 
JCV genome in the CSF. 
In particular, neuropathologic changes characteristically associated with NDLE 
include formation of multinucleated gianT-cells, microglial nodules and astrogliosis 
in the white matter, basal ganglia and neocortex [145]. 
First Langford and colleagues [146] described autoptic findings of a severe form of 
NDLE, in seven patients who failed HAART. In the brain of thiese patients, they 
found only HIV, but no other pathogens. Moreover, the tissue injury in these cases 
was confined to the white matter, and the leukoencephalopathy they described was 
more severe than that described prior to the use of HAART. 
They identified three stage of severity of this form of leukoencephalopathy, which 
were correlated with ante-mortem clinical, neuropsychological, and neuroimaging 
findings. These stages suggest a temporal sequence of pathologic events. In their 
model, leukoencephalopathy begins with perivascular infiltration by HIV-infected 
monocytes and BBB damage, leading to local HIV replication, moderate myelin 
loss, but limited gliosis. As disease progresses, more myelin is lost and is 
eventually accompanied by axonal damage and extensive astrogliosis. 
While the etiology is unclear, the condition's occurrence in the post-HAART era in 
highly treatment-experienced individuals strongly argues that antiretroviral therapy 
plays a basic role in pathogenesis. 
HIV-associated leukoencephalopathy may simply be a consequence of 
antiretroviral therapy that extends the survival of patients with HIV-encephalopathy 
without completely controlling HIV replication in the brain. Alternatively, its etiology 
may be more complex, involving other HIV-, immune-, and drug-mediated effects.  
 
28 
 
1.2 The Human Polyomaviruses 
The family name Polyomaviridae derives from the observation that the first member 
of this family could induce multiple (poly) tumors (oma) in mice [147]. 
Polyomaviruses were historically categorized with the Papillomaviruses under the 
designation of Papovaviruses until the separation into two distinct families in 2000 
[148]. 
Polyomaviruses (PyVs) are small, naked viruses with icosahedral capsid and 
circular, double-stranded DNA genomes and they have been isolated from a 
number of species, including human, monkey, rabbit, rodents, and birds. Their host 
range is rather restricted, and they generally do not infect other species 
productively [149]. Simian virus 40 (SV40) and mouse Polyomavirus are the 
prototypical and most well characterized member of the Polyomaviridae family 
[150]. 
Human are the natural host for two members of the Polyomaviridae family, JCV 
and BK virus (BKV), both isolated in 1971 from the urine of a kidney transplant 
recipient with the initials B.K, who developed uretheric stenosis, and from the brain 
tissue of a Hodgkin lymphoma patient with the initials J.C. who suffered from PML, 
respectively [151,152]. 
JCV is defined as the etiological agent of PML. BKV has been identified as the 
main cause of Polyomavirus-associated nephropathy (PVAN), the major cause of 
renal allograft failure. 
Recently, eight novel human Polyomaviruses (HPyV) have been identified. In 2007, 
the HPyV KI and WU were characterized in nasopharyngeal aspirates of children 
with acute respiratory symptoms at the Karolinska Institute and at the Washington 
University, respectively [153,154]. 
In 2008, Merkel cell Polyomavirus (MCPyV) was isolated from a rare skin tumor 
named Merkel cell Carcinoma (MCC) [155], and in 2010 the novel HPyV6 and 
HPyV7 were characterized from skin swabs of healthy individuals [156], though 
they have not been associated with any human disease. Trichodisplasia spinulosa-
associated Polyomavirus was identified in a boy suffering from this rare skin 
disease characterized by the development of follicular papules and keratin spines 
[157]. Viral DNA sequences of HPyV9 were amplified from a serum of a kidney 
transplant patient [158], and, lastly, HPyV10 was isolated few month ago from 
condyloma specimens of a patient with warts, hypogammaglobulinemia, infections, 
and myelokathexis syndrome [159]. 
Primary infection with both BKV and JCV is usually asymptomatic. BKV commonly 
infects young children and adult seroprevalence rates of 65-90% being reached by 
the age of ten years. In contrast, the pattern of JCV infection appears to vary 
between populations; in some anti-JCV antibody is acquired early as for BKV, but 
in others anti-JCV antibody prevalence continues to rise throughout life. This 
indicates that the two viruses are probably transmitted independently and by 
different routes. While BKV DNA is found infrequently in the urine of healthy adults, 
JCV viruria occurs universally, increasing with age, with adult prevalence rates 
often between 20% and 60% [160]. 
The primary infection is followed by a lifelong, subclinical persistence of episomal 
viral genomes in targeT-cells, and in the context of profound immunosuppression 
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the virus infection can be activated, leading to the destruction of tissues and 
diseases [161]. 
BKV and JCV can be detected in a variety of tissue, but BKV is considered a 
nephrotropic virus, whose-associated illnesses occur primarily in the urinary tract, 
and JCV a neurotropic virus, since its pathogenic effects are confined exclusively 
to the CNS.  
Both viruses have oncogenic potentials in animal models and cell culture, and viral 
DNA/ARNA and proteins can be detected in human tumors. However, their role in 
human cancer remains controversial [reviewed in 162]. 
1.2.1 Viral structure and genome 
JCV and BKV display a high degree of nucleotide sequence homology, of about 
75%, but, in spite of their high resemblance, these closely related polyomaviruses 
exhibit distinct biological behavior and disease pathogenesis [163,164]. 
Polyomaviruses are composed of small, non-enveloped, ichosaedral virion, 
measuring 40-45 nm in diameter and comprising 88% proteins and 12% DNA. The 
capsid is composed of three virus-encoded structural proteins, Viral Protein 1, 2, 
and 3 (VP1, VP2 and VP3). VP1, the most highly homologous among JCV and 
BKV, is the major component with 360 molecules per capsid, and VP2 and VP3 
contribute with 30-60 molecules each to the capsid. The ichosaedron consists of 72 
pentamers with no apparent hexamers, each composed of five VP1 molecules and 
one molecule of VP2 or VP3. Only VP1 is exposed on the surface of the capsid, 
and this determines the receptor specificity [119,149]. 
The capsid surrounds a single, super-coiled, double-stranded DNA molecule of 
5130 base pairs (bp) in the case of the prototype JCV genome Mad-1 strain or 
5153 bp as seen in the BKV Dunlop strain. The viral genome is associated with 
cellular histones H2A, H2B, H3 and H4 to form the so-called minichromosome, 
structurally indistinguishable from host cell chromatin; the viral particles do not 
contain linker histones, but the genome acquires them after entry into the host cell 
[119,150,149]. 
The viral genome of JCV and BKV is functionally divided into three regions, called 
the genetically conserved early and late coding regions, of about the same size, 
which are separated by the hypervariable non-coding control region (NCCR), 
containing the origin of viral DNA replication (ori), the TATA box, binding sites for 
cellular transcription factors and bidirectional promoter and enhancer for the 
transcription of early and late genes. The NCCRs of polyomaviruses are the most 
variable portions of the viral genome within a single virus as well as across genera 
of viruses 
Viral DNA transcription and replication occurs bidirectionally starting from the 
NCCR: the early transcription proceeds in a counterclockwise direction, while the 
late transcription proceeds clockwise on the opposite strand of DNA [135]. 
The early coding region spans about 2.4 kb and encodes the alternatively spliced 
transforming proteins large tumor antigen (T-Ag) and small tumor antigen (t-Ag), 
which are involved in viral replication, and in promoting transformation of cells in 
culture and oncogenesis in vivo. T-Ag, a nuclear phosphoprotein of approximately 
700 amino acids (aa), is considered the master regulator of the infectious process, 
because it orchestrate the production of early pre-messenger RNA (mRNA), the 
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initiation of viral DNA replication and the activation of late gene transcription. 
Moreover, binding to the hypophosphorylated form of the retinoblastoma 
susceptibility protein (pRb), T-Ag allows for premature release of the transcription 
factor E2F, which stimulate resting cells to enter the S-phase of the cell cycle. 
Thus, T-Ag directly recruits the host cell DNA polymerase complex to the ori in 
order to initiate bi-directional DNA synthesis. Activation of the late viral promoter by 
T-Ag and associated cellular transcription factors leads to viral late gene 
expression [reviewed in 150]. 
t-Ag is a cysteine-rich protein of 172 aa in BKV and JCV, the first 80 of which are 
shared with T-Ag. t-Ag role in the lifecycle of human polyomaviruses is not yet fully 
understood, though it is believed to serve an ancillary role fot T-Ag activity and cell 
transformation [135,165]. 
Additional T antigen isoforms have also been identified in JCV and BKV: JCV 
encodes three T’ antigens, T’165, T’136, and T’135 [166] and BKV encodes a 
truncated T antigen close in structure to T’136 of JCV [167]. The late coding region 
spans 2.3 kb and contains the genetic information for the major structural protein 
VP1 and the two minor structural proteins VP2 and VP3, that are encoded from a 
common precursor mRNA by alternative splicing. The late region also encodes the 
agnoprotein, which role in the polyomavirus life cycle remains under investigation, 
but appears to be multifunctional, and varied functions have been attributed to it, 
ranging from viral transcriptional regulation to inhibition of host DNA repair to 
functioning as a viroporin [150,168]. 
1.2.2 The infectious lifecycle of polyomaviruses 
Receptors: the infectious lifecycle of polyomaviruses is divided into an early and a 
late stage. The early stage begins with the initial interaction of the virus with the 
surface of the host cell and continues until the onset of viral DNA replication. The 
late stage includes all events that lead to the assembly of new virions and 
concludes with the release of viral progeny, which represents the completion of the 
entire viral replication cycle [150]. 
The infection of cell by polyomaviruses is initiated by the interaction of VP1 with 
specific receptors and co-receptors. It is known that BKV uses gangliosides GD1b 
and GT1b for the initial interaction with susceptible cells. More recent experiments 
argue that an N-linked glycoprotein with α(2,3)-linked sialic acid serves as the 
receptor for BKV on host cells. The identity of the proteinaceous component of the 
cellular receptor(s) for BKV remains to be determined [reviewed in 150]. 
JCV also requires sialic acid to infecT-cells and has been reported that it uses both 
α(2,3)- and α(2,6)-linked sialic acids to infect permissive glial cells [169].  Recently, 
a receptor moiety used by JCV for productive infection has been identified and a 
recombinant JCV VP1 pentamer has been shown to bind specifically to lactoseries 
tetrasaccharide C (LSTc), which contains a terminal α(2,6)-linked sialic acid. It 
appears likely that JCV primarily uses α(2,6)-linked sialic acids to bind to cells, with 
the possibility that the weak interactions between JCV and α(2,3)-linked sialic acids 
play a limited role in infection. It is currently unknown onto what receptor molecule 
the LSTc moiety is attached [170]. 
In addition to using sialic acid as a receptor, JCV has been shown to require the 
serotonin receptor, 5HT2A, to infect glial cells [171]. 
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The 5HT2A receptor protein contains several potential glycosylation sites, but it is 
unclear whether LSTc or other sialic acid moieties responsible for infection reside 
on this protein. Elimination of glycosylation sites on 5HT2A receptor obstructs 
receptor expression of the cell surface, preventing a clear consensus on the need 
for sialic acids on 5HT2A for infection. Additionally, gangliosides may play a role in 
JCV infection, and the ganglioside GT1b has been reported to function as a 
receptor for JCV [119,172]. 
Mechanisms of entry and intracellular trafficking: BKV and JCV penetrate into the 
cytoplasm by endocytosis, employing different internalization mechanisms to enter 
the host cell.  
BKV enters cells by caveolae-mediated endocytosis with a relatively slow process, 
while JCV enters rapidly and requires proper assembly of clathrin-coated pits. 
Inside the cell, BKV co-localized with the caveolae marker Cholera toxin subunit B 
and JCV with the clathrin marker, transferrin, in endosomes. 
After penetration into the interion of the cell, BKV and JCV are next transported 
through the cytosol to the nucleus, depending on the active cytoscheletal transport 
machinery. Close examination of the involvement of the cytoscheletal components 
demonstrated a critical role for intact microtubules during early infection by both 
BKV and JCV. 
In the nucleus: uncoating of polyomavirus occurs inside the nucleus, the site of 
viral replication and virion assembly. Here, the viral lifecycle is regulated by a 
temporal setting, according to which there is primarily the transcription of the early 
viral genes T-Ag and t-Ag upon entering the nucleus, followed by a switch to DNA 
replication. Afterwards, there is a second switch to the expression of late viral 
genes, VP1, VP2, VP3 and agnoprotein. 
In the nucleus of a permissive cell, the primary transcript is expressed from the 
early region and is alternatively spliced to give two mRNAs encoding T-Ag and t-
Ag. Subsequent to early transcription is the switch to DNA replication, primarily 
initiated by T-Ag, which complexes with host cell DNA polymerase α-primase and 
replication protein-A at the viral ori, and unwinds the double helix, promoting DNA 
synthesis [173]. 
Polyomaviruses rely on cellular enzymes and cofactors for DNA replication. Since 
these proteins are expressed in the S-phase of the cell cycle, T-Ag modulates 
cellular signaling pathway and stimulates the cell cycle, though its ability to bind a 
number of key cellular proteins that control cell cycle progression and apoptosis. In 
this manner T-Ag can direcT-cells to enter the S-phase thus enabling DNA viral 
replication. 
Once the viral genome has been replicated, T-Ag mediates repression of early 
gene expression, and stimulates transcription of the late genes. Finally, the capsid 
proteins VP1, VP2, VP3, expressed from the late region and localized into the 
nucleus, assemble with the replicated viral DNA to form a newly packaged virion 
progeny, which are released upon cell lysis [174] (fig. 8).   
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Fig. 8: life cycle of polyomaviruses in a permissive cell. The following steps are 
indicated: 1: binding of the viruses to cell surface receptors; 2: internalization into 
the cytosol by endocytosis; 3: transport to the nucleus; 4: uncoating; 5: 
transcription of the early region; 6: viral DNA replication; 7: transcription of the late 
region; 8: assembly of the viral progeny in the nucleus and new virions releasing 
from the cell. 
 
 
1.2.3 JCV 
JCV is a ubiquitous human polyomavirus that cause primary infection during late 
childhood, typically subclinical or linked to a mild respiratory illness: in some urban 
areas the rate of JCV seroconversion may exceed 90%. Between the age of 1 and 
5 years, approximately 10% of children demonstrate antibody to JCV, and by age 
of 10 years it can be observed in 40-60% of the population. By early adulthood, as 
many as 70-80% of the population has been infected.  
The mode of transmission for JCV is not yet well defined, however, the presence of 
JCV DNA in B-cells and stromal cells of the tonsils and oropharynx supports the 
hypothesis of a respiratory transmission, with tonsils serving as the potential site 
for initial infection [175]. JCV is found also in raw sewage, suggesting that ingestion 
of contaminated water or food could be another portal of virus entry [176-178], and 
in a high percentage of normal tissue samples taken from the upper and lower 
human gastrointestinal tract [179,180]. 
Once the primary childhood viremia is restricted by the action of immune system, 
particularly cell-mediated immunity, the virus is proposed to remain in the body in a 
state referred as viral latency, with periodic re-expression during periods of 
immunosuppression. The JCV latent state is not well understood but is thought to 
involve an asymptomatic, chronic, persistent infection wherein JCV DNA but no 
proteins are detected. Presumably, the circular viral genome is present as an 
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episome (latency), or alternatively viral DNA replication may occur sporadically or 
intermittently at a level below the threshold of detection (persistence), and this may 
depend on the tissue [84]. 
Many tissues have been reported to harbor latent JCV, including kidney, though to 
be the major organ of JCV persistence during latency, tonsils, spleen, lymph node, 
lung, bone marrow, and certain type of peripheral blood leukocytes, including B 
lymphocytes. Importantly, it has been reported the presence of JCV in the brain of 
healthy individuals without PML. Regarding the kidney, active viral replication is 
probably occurring episodically in the urothelium, because virus can sometimes be 
detected in the urine [84]. 
JCV, as the other human polyomavirusess, causes significant disease primarily in 
individuals that are immunocompromised, allowing reactivation from the persistent 
subclinical state to a lytic infection resulting in viruria and viremia, potentially 
leading to severe or fatal diseases [181]. The most common underlying cause of 
immunosuppression leading to JCV reactivation is AIDS. Reactivation results in the 
lytic infection of oligodendrocytes in the brain and the development of the fatal 
demyelinating lesions observed in the case of PML. 
Other immune-altering conditions, in which cases of PML have been reported, 
include lymphoproliferative diseases, such as lymphomas and leukemias, 
myeloproliferative diseases, organ transplants, chemotherapy, inherited 
immunodeficiencies, and treatment with immunomodulatory compounds, mainly 
some monoclonal antibodies [130,182,183]. 
There has been much debate on the nature of latency and its site(s) within the 
body, and it is still incompletely understood how the virus infects the CNS. In 
summary, there are two main hypotheses [84]. First, JCV latency and reactivation 
involves immune cells, especially B-lymphocytes in bone marrow, which acts as a 
source of latent virus and allow virus to circulate around the body and enter the 
brain [85,90]. Second, JCV DNA may be present in the brain prior to PML, and 
event(s) related to immunosuppression or HIV-1/ AIDS initiate viral replication; that 
is, the brain is the site of JCV latency and reactivation. In the CNS, JCV is possibly 
controlled by T-cells that migrate there. In the situation of an alteration of the 
immune system, possibly this control of the virus in the CNS is reduce and viral 
infection emerges. In addition, infection with different viral variants during a lifetime 
is not excluded and some of these variants are more likely to lead to CNS infection 
in the situation of a compromised immune response. Although no clear consensus 
has emerged about the nature and site of JCV latency, these two hypotheses are 
not mutually exclusive [90,129]. 
1.2.3.1 JCV genome 
Similar to the case for all other polyomaviruses, the JCV genome is a closed, 
circular, supercoiled DNA molecule that is composed of early and late genes, 
separated by the 400 pb NCCR or untranslated transcriptional control region 
(TCR), which contains the origin of replication, promoter, and enhancer elements  
(fig. 9) [184]. The early region is expressed de novo after infection and before DNA 
replication and is on the ori-proximal side of the NCCR. Late genes are optimally 
expressed concurrently with or after DNA replication and are found on the ori-distal 
side of the NCCR [reviewed in 119]. 
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The NCCR lies between the early and late coding sequences and is thought to be 
the main determinant of cell type specificity. Indeed, sequence modification in this 
promoter/enhancer structure can alter the cellular host range and may allow JCV to 
switch between states of lytic and latent infection. 
NCCR is composed of fairly well-conserved flanking regions that border the 
transcription start sites of the early and late coding regions, as well as a central 
region containing numerous transcription factor binding sites [119,185]. 
The NCCR varies greatly between isolates from PML patients. In addition, a 
sequence, known as archetype, has been isolated from urine specimens from both 
PML patients and healthy people but is rarely found in PML brain tissue. The 
original sequence isolated from the brain of a PML patient is known as Mad-1, as it 
was isolated at the University of Wisconsin- Madison. 
 
 
 
 
 
Fig. 9: schematic representation of JCV genome organization. The circular, double-
stranded DNA genome is ~5.2 kb in size and is divided into the early coding region 
and the late coding region, transcribed in opposite directions from a common 
NCCR. Early genes include T-Ag, t-Ag, T’135, T’136 and T’165. Late genes include 
agnoprotein, VP1, VP2 and VP3. 
 
 
Naturally occurring variants: the JCV regulatory region can be divided into 7 distinct 
sequence sections, all containing promoter/enhancer elements. The 128 bp region 
that immediately precedes the early coding sequences includes the origin of viral 
DNA replication. Opposite the direction of early transcription, starting 12 bp 
downstream from the center of the ori, sequence sections designated as a (25 bp), 
b (23 bp), c (55 bp), d (66 bp), e (18 bp), and f (69 bp) constitute the so called 
archetype sequence (fig. 10). The archetypal form of the virus is found in the 
kidney and urine of healthy and immunosuppressed individuals. It is typified by the 
CY strain of JCV and may represent the transmissible form of the virus. Despite the 
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presence of functional protein-coding regions and an ori, archetypal NCCRs do not 
support robust growth in culture [90,185]. 
Repeats and/or deletions from the archetype sequence account for all other known 
regulatory region variants [186]. 
 
 
 
 
 
Fig. 10: linear representation of JCV archetype NCCR sequence from [185]. 
Modified nucleotide-numbering system adapted from the prototype JCV genome, 
Mad-1 (Frisque et al, 1984). The archetype NCCR contains a single copy of all 
sequence sections observed in all other variant forms of JC virus regulatory region. 
From the early side, the initial regulatory region sequence section contains the ori 
followed by sequence sections designated a, b, c, d, e, and f . The base-pair length 
of each sequence section is noted.  
 
 
When present, the sections b and d have been shown to inhibit the efficient 
transcription and replication of JCV. Duplication of any singular grouping of section 
a through e in tandem sequences is thought to enhance level of viral activity, even 
if the tandem sequences experience substantial nucleotide deletions. The f 
sequence section usually follows any singular or repeated grouping of sections a 
through e and precedes the late coding regions [185]. 
The regulatory region amplified from PML brain and CSF usually show 
rearrangements generated by point mutation, base sections insertions and 
deletions compared to the archetype. In particular, the NCCR from the original 
isolate of JCV, Mad-1, is characterized by two deletions and a duplication, in 
comparison to the archetype. It contains an enhancer element, which exist as a 98 
bp tandem repeat, and duplicated TATA boxes as well as multiple transcription 
factor binding sites (fig. 11). The tandem repeat structure of the Mad-1 NCCR 
variant has been termed the prototype JCV NCCR sequence and is composed of 
the three sequence sections a, c and e, with the TATA boxes found in a. The Mad-
4 variant is identical to Mad-1 except that the NCCR contains a 19-bp deletion that 
eliminates the second, late-proximal TATA box. 
In addition, numerous NCCR variants containing a tandem repeat-like structure, 
and generally termed rearranged forms, have been isolated from tissues of patients 
with PML. These forms present some level of sequence section b and d 
integration, but also contain repeated sequences. Although Mad-1 was the first 
sequenced NCCR isolated from a PML patient and is referred to as the prototype, it 
appears to be a somewhat atypical isolate. The tandem repeat sequences serve as 
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a good reference point and newly isolated JCV sequences are generally compared 
to the Mad-1 variant. 
 
 
 
 
 
Fig. 11: the JCV NCCR detected in the brain or CSF of patients with PML usually 
consists of tandem repeats of a 98 bp element, as in the Mad-1 strain; most 
isolates from the urine of healthy individuals and patients with PML are similar to 
the archetype regulatory region (quiescent in the kidneys after asymptomatic 
primary infection). The JCV archetype has one 98-bp element with a 23-bp insert 
and a 66-bp insert.  
 
 
Because the prototype NCCR contains a repeat structure, it contains significantly 
more binding sites for transcription factors essential to viral gene expression. In 
particular, the archetype sequence does not contain the Oct-6/tst-1/SCIP sites 
present on the border between regions c and e. Additionally, the lack of 
neighboring a and c regions eliminates Spi-B binding sites, which are important for 
early viral gene expression [187]. The lack of binding sites for brain-specific 
transcription factors may be what abrogates the ability of archetype virus to cause 
disease in the brain. The lack of repeats of region c in archetype also leads to a 
reduced number of NFI binding sites, which allow a family of transcription factors to 
bind the JCV genome and are essential for fully activating viral transcription in the 
brain and cells of the lymphoid system. These results indicate the importance of 
selective repeated binding sites for the cellular transcription factors involved in 
activating viral gene expression. 
The mechanism for derivation of prototype sequence from archetype and 
dissemination of archetype in the host have yet to be demonstrated, although the 
prevailing model holds that archetype-like sequences are transmitted from person 
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to person and then undergo deletions and duplications within the infected host, 
leading to PML-type NCCR sequences, which traffic to the brain. This 
rearrangement of the NCCR may take place in lymphoid cells like B-cells, since 
they possess the Rag1 and Rag2 enzymes for immunoglobulin gene 
rearrangements.  
In order to classify newly sequenced viral NCCRs, a compass-like classification 
scheme that organizes NCCR sequences into four distinct variant types was 
developed [185]. Variant type I NCCRs contain no inserts in the a-c-e organization 
of the NCCR and can be divided into variant type I-S (singular a-c-e) and variant 
type I-R (a-c-e repeat with no inserts) (Mad-1 and Mad-4). Variant type II NCCRs 
contain inserts into the a-c-e sequence and can be classified as variant type II-S 
(a-b-c-d-e, or archetype-like) or variant type II-R (containing inserts and repeats) 
(e.g., Mad-7 and Mad-8) (fig. 12 and table 1). 
 
 
 
 
 
Fig. 12: the Compass: a schematic diagram of the relationships between JCV 
regulatory region sequences published worldwide (adapted from [185]). JCV 
variant NCCR grouped into quadrants (I-S, I-R, II-S, and II-R). Upper quadrant 
variant types (I) have no additional sequence integrated into the a-c-e units (no 
inserts). Lower quadrant variant types (II) have dark integrated sequence sections 
(inserts), b (23 bp) and d (66 bp). Both types I and II are divided into singular (S) 
and repeat (R) forms by the left and right quadrants, respectively. Dots represent 
sites of possible bp deletions. 
Right quadrants (R-forms) have dark dashes where sequence is deleted and + 
where additional repeats may occur. JCV tropism common to all variant regulatory 
region forms is contained in dark central circle. Specific JCV tropisms are 
contained in dark corner triangles.  
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Table 1: NCCR variants. 
 
Variant 
Type 
NCCR 
Structure 
Tissue Association Example NCCR sequence 
block variations* 
Disease 
association 
IS Singular, 
no insert 
GI tract, bone marrow  a c e                f Colon cancer? 
IR Repeats, 
no insert 
GI tract, tonsil, bone 
marrow 
Mad-1 a c e       ace   f PML 
IIS Singular, inserts 
Lymph node, lung, 
tonsil, liver, urine 
Archetype abcde              f Urine (non-
pathogenic) 
IIR 
Repeat, 
inserts 
Lymph node, lung, 
tonsil, liver, spleen, 
urine 
Mad-8 abc  +e  bc+e  f PML 
* +, one base insertion; lowercase letter, full sequence block; italic b, partial sequence block. All variants 
are found in the brain and peripheral blood lymphocytes. 
 
 
Viral genotypes: VP1 genotyping region is the other polymorphic part of the JCV 
genome, first recognized by serology and restriction fragment length 
polymorphisms and then defined by sequencing of different isolates and strains by 
which at least eight different viral genotypes and several subtypes have now been 
described. 
Since JCV transmission from parent to offspring allow the same genotype to persist 
for generations within a population, many genotyping studies have been carried out 
in diverse population group to associate different types of JCV with populations of 
various descent as well as to map population movements. It has been 
hypothesized that type 6 is the original JCV type and that JCV coevolved with 
human populations. 
Type 1 and type 4 are generally associated with Europeans and European-
Americans, while type 2A is found generally in Asians and Native American 
populations. Types 3 and 6 are isolated primarily from Africans and African-
Americans. Types 2D and 7C are found among both Asians and South Asians 
[188,189]. Types 2E, 8A, and 8B are found in Western Pacific populations [189]. 
Interestingly, type 8A is found only in populations of Papua New Guinea [190]. JCV 
subtype 2B, which is more often found among Asians and Eurasians, is reported to 
be the most frequently found in the brain of PML patients than expected on the 
basis of its prevalence in urine samples from a control normal population; on the 
contrary, type 4 has been associated with lower disease risk [191] (table 2). 
More recently, investigation of changes in viral DNA coding regions from brain 
biopsy specimens and CSF specimens from PML patients has been undertaken. 
Alterations in structural protein amino acid sequences could lead to enhanced viral 
entry and thus contribute to PML or, alternatively, could potentially cause distinct 
diseases. Some evidences point to the association of mutations of certain amino 
acid residues in the region of the sialic acid binding sites and surface loops of VP1 
with PML and that these mutations occur within the patient after initial infection with 
JCV [reviewed in 119]. 
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Table 2: VP1 types and associated ethnic groups (from [119]). 
 
Type VP1 type change(s) from consensusa Predominantly associated 
ethnic group 
Identical VP1 
sequence 
1A 75R, 117S, 158L, 345K European/ European American  
1B 74S, 117S, 126A European/ European American  
2A1 113(L), 117(A), 126(A), 164(T) Asian/ Native American  
2A2 115L Asian/ Native American  
2Bb 126A Asian/ Eurasia  
2D1 Consensus Asian/ South Asian 7C1, 7C2 
2D2 126A Asian/ South Asian 2B 
2E 113L, 321I Western Pacific populations 7A 
3A 134A, 164T, 321I, 332Q African/ African American 3B 
3B 134A, 164T, 321I, 332Q African/ African American 3A 
4c 134A, 164T European/ European American  
6 164T African  
7A 113L, 321I Asian 2E 
7B1 113(L) Asian  
7B2 37V, 321I Asian  
7C1 Consensus Asian/ South Asian 2D1, 7C2 
7C2 Consensus Asian/ South Asian 2D1, 7C1 
8A 12H, 164T Inhabitants of Papua New Guinea 8B 
8B 12H, 164T Western Pacific populations 8A 
 
aParentheses indicate that the change is found in less than 50% of the type; bslightly higher PML risk; 
cslightly lower PML risk. 
 
 
1.2.3.2 JCV tropism 
The strict species specificity of JCV for humans has confounded the development 
of animal models for PML. 
In vivo, JCV infection is likely restricted to kidney epithelial cells, tonsillar stromal 
cells, bone marrow-derived cell lineages, oligodendrocytes, and astrocytes 
[reviewed in 119]. 
The virus is thought to establish low-level persistent or latent infections in the 
kidney and in bone marrow-derived cells largely due to inefficient viral replication in 
these cell types. Once in the central nervous system (CNS), the virus replicates 
vigorously in oligodendrocytes, leading to the demyelinating disease PML. 
The cell type-specific tropism of JCV observed in vivo is mirrored in vitro, with virus 
productively infecting bone marrow-derived cells, tonsillar stromal cells, and 
macroglia [reviewed in 119]. Virus replication is maximal in primary human fetal 
glial cell cultures and in some human glial cell lines [193], as well as in other cell 
lines expressing SV40 T-Ag, such as COS-7 cells [192,193]. 
The major tropism of JCV for human glial cells is not fully understood, but multiple 
factors are likely responsible for contributing to robust viral replication in this cell 
type. Host cell- and species-specific transcription and replication factors contribute 
significantly to the restricted specificity displayed by JCV and other members of the 
genus [194,195]. In addition, virus receptor interactions contribute to viral tropism 
and spread. 
Tropism for glial cell may be determined at the level of viral early gene 
transcription, which is responsible for the production of T-Ag protein. Several lines 
of evidence indicate that the JCV early promoter is preferentially expressed in glial 
cells. For example, recombinant DNA construct, in which the JCV early promoter is 
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linked to a reporter gene, show much higher level of expression in glial cells than in 
non-glial cells [196]. Transgenic mice with the JCV early region selectively express 
T-Ag in oligodendrocytes leading to a phenotype of dysmyelination [197]. In 
addition, transgenic mice with constructs in which the early promoter and T-Ag 
regions of JCV and SV40 were exchange showed patterns of expression that 
demonstrate the JCV early promoter, and not the T-Ag coding sequence, is 
responsible for glial cell expression [198]. In vitro transcription assay showed that 
hamster glial cell extract stimulated the JCV early promoter whereas HeLa cell (an 
immortal cell line derived from cervical cancer) extract reduced production of 
nuclear run-off transcripts. This suggests that glial cells contain one or more an 
activating factors for transcription of JCV early promoter, while non-glial cells 
contain a transcriptional repressor [199,200]. 
1.2.3.3 Oncogenicity of JCV 
The first evidence on the association of JCV with cancer came from reports of brain 
tumors found in patients with concomitant PML. 
JCV is able to transform cells in culture, particularly cells of glial origin including 
human fetal glial cells and primary hamster brain cells. JCV-transformed cells 
exhibit the phenotypic properties associated with transformation including growth in 
soft agar, serum-independence, changes in morphology, plasminogen activator 
production, etc. The transforming ability of JCV appears to be limited to cells of 
neural origin and cell-type-specific transcriptional regulation of the viral promoter is 
thought to be responsible for this property [201]. 
Many studies have established the highly oncogenic potential of JCV when injected 
into laboratory rodents and JCV is the only human virus that induces solid tumors 
in non-human primates. Transgenic mice with the JCV T-Ag gene develop a variety 
of neural tumors. In humans, there have been many reports on the presence of 
JCV DNA sequences and T-Ag expression associated with some brain and other 
tumors [135].  The presence of JCV is been investigated in a broad range of glial-
origin tumors including oligoastrocytomas, astrocytomas, anaplastic astrocytic, 
anaplastic oligodendroglial, glioblastomas and ependymomas. JCV DNA has been 
detected in nearly every known type of malignant and non-malignant tumors which 
arise from cells of the CNS [202]. 
It is interesting to note that JCV DNA and viral T-Ag protein has been detected at 
very high percentages, at similar seen in the CNS-origin tumors, in the colon 
tumors. The prevalence of JCV sequences and T-Ag in these tumors suggests that 
these cell types are permissive for the expression of the JCV early promoter, which 
may lead to the accumulation of T-Ag and potential cellular transformation. This 
evidence, taken together with other potential sites of latency in humans, including 
B-cells and kidney epithelium, suggest areas of further study to investigate the 
presence of JCV in normal and tumor tissues of non-CNS origin [202]. T-Ag and t-
Ag are the viral molecule that mediate the oncogenic potential of JCV. The T-Ag is 
thought to be the primary agent in transforming cells, and it interacts with a 
plethora of cellular proteins that are responsible for driving cells into S phase. Two 
of these regions alter the pRb related tumor suppressor proteins, which normally 
binds to transcription factor E2F. Free E2F activates transcription of genes involved 
in DNA synthesis, while binding of E2F by pRb represses these genes. 
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Phosphorylation of pRb releases E2F, and leads to progression of the cell cycle 
and growth. The J domain of T-Ag, located near the N-terminal, affects pRb by 
mediating degradation of pRb complexes. The N-terminus contains another domain 
which binds to these pRb complexes. 
A region of T-Ag has the ability to bind p53, whose normal function is to detect 
DNA damage in the cell and either pause the cell cycle or to activate an apoptotic 
program. Aside from these pathways, there is evidence that T-Ag can alter the 
human chromosome in other unspecified ways. 
The t-Ag has a homologous N-terminus when compared with T-Ag, but it has a 
unique C-terminal end. It has been suggested that t-Ag may help transform cells 
during times of stress, such as nutrient starvation, which would normally suppress 
proliferation. 
1.2.3.4 JCV pathogenesis 
JC virus infection is species-specific and it is only found in humans. Therefore, 
research on JCV pathogenesis has been hampered by the lack of an animal 
model. While all JCV infected oligodendrocytes appear to sustain a productive 
infection, some astrocytes do also harbor late JCV genes and are destroyed, while 
other may sustain an abortive infection and appear transformed [87]. A model for 
JCV pathogenesis is shown in fig. 13: the initial site of infection is assumed to be 
tonsillar stromal cells, from which JCV is disseminated by lymphocytes to bone 
marrow CD34+ cells and uroepithelial cells in the kidney, presumed sites of 
latency. Reactivation occurs during immunosuppression or immune modulation, 
after which it gains entry into the brain by way of peripheral B lymphocytes. 
Susceptible cells (oligodendrocytes, astrocytes, and progenitor cells) share a 
characteristic expression pattern of nuclear transcription factors required for 
synthesis of JCV early viral protein mRNA and replication of JCV DNA. 
 
 
 
 
 
 
Fig. 13: a model for pathogenesis of JCV infections (from [203]). 
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1.2.3.4.1 JCV and PML 
As described above, primary infection of JCV is asymptomatic and occurs in 
immunocompetent individuals early in childhood. Profound immunosuppression 
provides suitable condition for increase in JCV replication and spread to the CNS, 
where the virus selectively targets and destroys the myelin-producing glial cells, the 
oligodendrocytes. Immune compromising condition includes AIDS, lymphoid 
system cancers, such as lymphomas, or long-term immunosuppressive therapy for 
treatment of cancer or autoimmune diseases [119,152,204]. 
Patients who undergo organ transplant are also at risk due to the need for 
chemotherapy to prevent organ rejection [205]. Asymptomatic viruria can occur in 
old age, pregnancy, and diabetes mellitus, presumably as a result of hormonal 
effects on anti-viral immunity [206]. 
The loss of oligodendrocytes results is a patchy and subsequent confluent 
demyelination of the CNS referred to PML [83]. Development of PML proceeds as 
a stochastic event. Based on current incomplete understanding, it is possible to 
speculate a plausible scenario for PML development (table 3). 
Following the primary infection, JCV disseminates and establishes latency in 
various sites within the body. Latency in the brain remains controversial because 
some investigators have detected JCV DNA but not protein expression [207], and 
others have found the T-Ag, but rarely [208]. Based on the pervasive presence in 
urine of the archetype JCV, it is likely, but not proven, that the primary infection 
occurs with this strain, incapable of an efficient replication in glial cells. It would 
then require genetic modification, in particular a 98 bp tandem repeat in its 
regulatory region to become neurotropic. 
 
 
Table 3: the proposed stages of development of PML (adapted from [209]). 
 
Initial infection of JCV 
1. Establishment of JCV latency, most importantly in CD34+ and 
other B-cell lineages 
2. Release of B-cells (immature and pre-B-cells) from bone marrow: 
a) re-activation of JCV within this immature B-cells due to viral 
transactivation by transcriptional factors that are released during 
B-cell maturation 
b) Mutation of JCV to a neurotropic form within the B-cells that 
have the unique genetic machinery to permit this, namely, 
machanisms for gene rearrangement, the addition or deletion of 
nucleotides to the genome, and somatic hypermutation 
3. Actively replicating neurotropic JCV in the circulation 
4. Brain entry of neurotropic JCV 
5. Establishment of productive infection of oligodendrocytes 
6. Impairment of CNS immunosurveillance: 
a) Inability of JCV-specific tcitotoxic T-cells to enter the brain 
b) Inability to process JCV antigen locally in the brain due to the 
depletion of perivascular dendritic cells 
 
 
It has been proposed that B lymphocytes, besides serving as a potential site of 
viral latency, may play an important role in the pathogenesis of PML. Since they 
can undergo a V(D)J recombination and have a unique genetic machinery that 
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facilitates gene rearrangements, it is possible that they could harbor recombination 
and/or rearrangements of viral genome (fig. 14). 
This hypothesis is sustained by the observation that diverse viral NCCRs, including 
archetype-like and prototype-like NCCRs, have been found in the blood and bone 
marrow [reviewed in 119, 210,211].  
During the latency into the B lymphocytes, it is possible that the virus is periodically 
re-expressed, ultimately trafficking to the brain and establishing a productive 
infection of oligodendrocytes. Alternatively, the virus is harbored latently within the 
brain and its expression suppressed by an effective immune response. In fact, B-
cells may carry JCV across the blood-brain barrier, where the virus may cross as 
free virus. JCV may also infect microvascular endothelial cells and thereby cross 
into the brain [101,212]. 
So, the primary working hypothesis for development of PML is that at least four 
events must occur for latent JCV to cause lytic infection of the oligodendrocytes in 
the brain: (i) the host immune system must be compromised or altered, (ii) the viral 
NCCR must acquire changes that increase viral transcription and replication in both 
B-cells and glial cells, (iii) DNA binding factors that bind to recombined NCCR 
sequence motifs must be present and/or upregulated in infected hematopoietic 
progenitor, B-cells, and/or glial cells, and (iv) free virus or virus in B-cells must 
cross the blood-brain barrier and be carried into the brain, where virus is passed to 
oligodendrocytes and lytic infection takes place. Once the virus is in the brain of the 
susceptible (immunocompromised) host, PML occurs. These events may occur in 
the bone marrow, in CD34+ lymphocyte precursors or B-cells in the periphery, or in 
the brain [119]. 
 
 
 
 
 
Fig. 14: genesis of the neurotropic strain of JCV (adapted from [185]). The JCV 
genome is depicted on the left. The archetype virus’ NCCR is at the top; at the 
bottom, is the 98 bp tandem repeat sequence seen in the virus isolated from brains 
with PML. This is the mutation that must occur. 
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1.2.3.4.2 Other JCV associated diseases 
JCV Granule Cell Neuronopathy (JCV GCN): whereas PML results from JCV 
infection of glial cells in the brain, JCV granule cell neuronopathy (JCV GCN) is 
caused by JCV infection of granule cell neurons in the cerebellum. Areas of cell 
loss in the granule cell layer were first described in up to 5% of PML patients prior 
to the era of HIV [213]. 
Granule cells with hypochromatic and enlarged nuclei were also seen in AIDS 
patients with PML, and JCV DNA was detected by PCR in the cerebellar biopsy of 
an AIDS patient with cerebellar atrophy [214,215]. 
This syndrome has now been described by several groups in both HIV-positive and 
HIV-negative patients, including one with sarcoidosis. JCV GCN can occur in 
isolation, or concomitantly to PML [reviewed in 107]. 
Since the granule cell neurons are destroyed by JCV, patients with JCV GCN 
present with subacute or chronic onset of cerebellar dysfunction, including gait 
ataxia, dysarthria and incoordination. Magnetic Resonance Imaging (MRI) shows 
cerebellar atrophy. In addition, cerebellar white matter lesions consistent with PML 
can also be present. Diagnosis is established by cerebellar biopsy, showing a lytic 
infection of granule cell neurons by JCV. In the proper clinical and radiological 
setting, JCV GCN can also be diagnosed by detection of JCV DNA by PCR in the 
CSF [107]. 
JCV encephalopathy (JCVE): although JCV mainly infects the brain white matter, 
gray matter infection can occur. 
A case of JCV induced gray matter disease was recently reported, secondary to a 
productive infection of cortical pyramidal neurons. 
The CSF JCV PCR was positive and the diagnosis was confirmed by histological 
examination which showed fulminant, productive and lytic JCV infection of the 
cortical pyramidal neurons and astrocytes, associated with laminar necrosis [216].  
JCV meningitis: although JCV is not routinely checked when patients present with 
meningitis, there are several published cases finding JC virus in the CSF of both 
immunocompromised and immunocompetent patients who presented with 
meningeal symptoms only. However, the prevalence of detecting JCV in CSF of 
patients presenting with meningitis has yet to be determined [217]. 
It is not clear in these cases whether infection was due to JC virus primary infection 
or reactivation. The presentation of JCV meningitis is consistent with typical 
meningeal symptoms, with no focal neurological deficits [218]. Unlike PML, there is 
no focal lesion in the white matter of the brain [219]. 
Diagnosis is confirmed with detection of JCV in the CSF along with the exclusion of 
all other neurotropic viruses. 
Treatment in JCV GCN, JCVE and JCV meningitis is the same as in classic PML, 
including HAART in HIV-positive patients, and removal of medications causing 
immunosuppression in HIV-negative individuals. 
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1.3 Natalizumab and PML 
On 28 February 2005, natalizumab was withdrawn voluntarily from the market after 
the occurrence of two cases of PML in patients participating in the SENTINEL trial 
(after 28 and 37 doses of natalizumab, respectively), approximately 1 month before 
study termination (1,003 of 1,171 MS patients had completed the study); one 
patient died and the other is still alive [220,221]. These two cases were soon 
followed by a case of PML in a patient with Crohn’s disease treated with 
natalizumab, who had previously received infliximab, azathioprine and oral 
corticosteroids (after eight natalizumab infusions) [222], representing an incidence 
of 1 case of Natalizumab-associated PML in 1,000 patients over a mean treatment 
period of 17.9 months [223]. Then, the drug was reintroduced in the USA and 
approved in numerous other countries in June 2006, basing on the notion that 
benefits for the course of MS outweigh the risks of contracting PML, and after the 
establishment of an intensive global risk management program. Accumulated 
safety data from this program have identified longer duration of natalizumab 
treatment, the use of immunosuppressants before the initiation of natalizumab 
therapy, and positive status with respect to anti-JC virus antibodies, as assessed 
with the use of a two-step anti-JC virus antibody assay (STRATIFY JCV, Focus 
Diagnostics), as risk factors for PML [reviewed in 224].  
Since the therapeutic activity of natalizumab in MS is thought to be a result of its 
ability to prevent activated lymphocytes from entering the CNS, and although 
natalizumab is not a classical immunosuppressant, the inhibition of leukocyte and 
monocyte migration may have implications for the immune system surveillance. 
The relationship between natalizumab treatment and the appearance of PML is still 
under investigation, but a number of studies have looked at the specific immune 
system effects of natalizumab in patients with MS, with a view toward better 
understanding the potential association between natalizumab treatment and PML. 
It is clear that treatment with natalizumab significantly suppresses the number of 
lymphocytes in the CSF [225], and this prolonged decrease of lymphocytes in the 
CSF may impair immune surveillance in the CNS, leading to JCV reactivation and 
the development of PML [225-227] (fig. 15).  
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Fig. 15: key speps proposed for the pathogenesis of natalizumab-associated PML. 
The initial event is primary infection with JCV, which establish a persistent 
infection. JCV subsequently develops adaptative mutations in the NCCR and VP1 
region, allowing the development of pathogenic neurotropic virus with specificity for 
glial cells. A failure in CNS immune surveillance is required before the patient 
develops overt PML and natalizumab may lower the threshold for the development 
of PMLat various levels, as by inhibiting CNS immune surveillance. 
 
 
There are several differences between natalizumab-associated PML compared 
with PML in the contest of HIV or malignancy. First, several clinical observations 
should increase suspicion of natalizumab-associated PML. The most common 
presenting sympoms are cognitive, motor, language, and visual impairment. 
Second, although the MRI findings are similar to those of classic PML, the 
neutralization of the immune system by the medication may lead to very destructive 
lesions which are rarely seen in other settings. In fact, unlike in classic PML where 
gadolinium enhancement is usually not seen in presentation, in about one half of 
natalizumab patients who developed PML there are gadolinium enhancement at 
diagnosis, indicating ongoing inflammatory host response to JCV. Seizures and 
paroxysmal events can occur at presentation, which help to differentiate PML from 
an MS relapse. 
The diagnosis of natalizumab-associated PML is established by PCR detection of 
JCV DNA in the CSF. However, because the viral copy number in the CSF may be 
very low (500 copies/ml or less), the CSF PCR may be falsely negative, and in 
several cases of PML brain biopsy may be necessary [228]. This low JCV viral load 
in the CSF may be explained by the cellular immune response to JCV at baseline 
observed in MS patients who developed PML after natalizumab treatment, unlike 
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HIV-1 positive PML patients who have significantly altered cellular immune 
response [229]. 
PML associated with natalizumab has a much higher survival rate compared with 
PML seen in other conditions, possibly because of early diagnosis achieved 
through clinical vigilance and swift immune reconstitution through natalizumab 
discontinuation and either plasmapheresis or immunoabsorption. In fact, 
natalizumab discontinuation is strongly recommended upon the first signs or 
symptoms and/or MRI findings suggestive of PML [207]. Presently, immune 
reconstitution, as a restoration of normal immune function, is the only intervention 
that has demonstrated proven efficacy for PML in both MS and other disease 
states. Nearly all patients with PML have undergone plasma exchange or 
immunoadsorption in order to more rapidly remove natalizumab from plasma and 
to speed up the reconstitution of immune surveillance [230,231].   
In considering the treatment of natalizumab-treated patients with MS who develop 
PML, stopping natalizumab is likely to precipitate IRIS. Indeed, if natalizumab is 
removed from the circulation by plasma exchange or immunoadsorption, IRIS will 
occur more rapidly, and PML is controlled more quickly [230]. 
Predictors of survival in natalizumab-associated PML include younger age at 
diagnosis, less disability (as measured by Expanded Disability Status Scale 
[EDSS]) prior to the onset of PML, more localized disease on MRI of the brain, and 
shorter time from symptoms onset to PML diagnosis [232]. 
1.3.1 Stratifying risk for natalizumab-associated PML  
Key steps in the reduction of risk associated with PML include 1) indentifying 
patients at increased risk of PML, 2) close monitoring of patients at risk of PML and 
heightened clinical vigilance for evidence of natalizumab-associated PML, 3) 
stopping natalizumab where PML is suspected 4) obtaining rapid and accurate 
diagnosis of PML, and 5) developing strategies for temporary or permanent 
discontinuation of natalizumab in patients where risk of PML is deemed to be too 
high [233]. 
PML cases identified so far, from pre- and post-marketing clinical studies on 
natalizumab, suggest that the following factors are associated with increased PML 
risk: 
• duration of the treatment 
• prior immunosuppressant use 
• JCV seropositivity 
PML incidence is calculated as the number of PML cases that develop during an 
interval divided by the number of patients who are ever been exposed to 
natalizumab for that time of period (either cumulative duration or 12-infusion 
treatment interval) [234]. The incidence, at present, is determined as 2.75 cases for 
1,000 natalizumab-treated MS patients, equal to 298 PML cases for 108,300 
natalizumab-treated patients. 
The analysis pertaining to the first 79 post-marketing cases (reported up to 
December 2, 2010) have highlighted as the duration of natalizumab dosing before 
PML diagnosis ranged from about 1 year to more than 3.5 years (mean 2 years) 
[reviewed in 235]. Incidence of PML over time was very low in the first 12 months 
48 
 
of treatment but thereafter increased up to 36 months. Thus, over the first two 
years, the duration of natalizumab exposure clearly relates to the development of 
PML (fig. 16), and PML risk increases with increasing treatment duration. PML risk 
may peak after 2 years of treatment or in the third year of therapy, corresponding to 
25-36 natalizumab infusions [234]. The number of patients treated for 4 years or 
more are too small and there are few data beyond this period to allow meaningful 
calculation of risk for these longer durations of treatment [234].  
 
 
 
 
 
Fig. 16: natalizumab-associated PML incidence by cumulative treatment duration 
(incidence estimates by treatment duration through 30 November 2011). 
 
 
After the diagnosis of two early PML cases in combined β-interferon/natalizumab 
treatment group of SENTINEL trial, it was suggested that the combination may 
predispose to the development of PML. Patients with MS who developed PML 
were more likely to have been treated with an immunosuppressant before receiving 
natalizumab compared with the overall natalizumab-treated population. 
Immunosuppressant use at any time before initiation of natalizumab treatment 
confers a 4-fold increased risk of developing PML, despite there being no evidence 
for residual immune suppression when natalizumab treatment was initiated. The 
most commonly used immunosuppressive agents in the natalizumab-associated 
PML patients were mitoxantrone, methotrexate, cyclophosphamide, azathioprine, 
cladribine, and mycophenolate mofetil (but not β-interferon or GA), but the risk 
does not appear to be associated with the type of immunosuppressive used, 
duration of use, or wash-out period between discontinuation of immunosuppressive 
and initiation of natalizumab [236]. 
Although it is not clear whether and how the addition of immunomodulatory or 
immunosuppressant therapy to natalizumab increases the risk of PML, and given 
the confirmed cases of PML in MS occurred in combination treatment, it seems 
reasonable that natalizumab should be indicated as monotherapy. In addition, the 
lack of data to determine whether natalizumab in combination with other drugs is 
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more effective than natalizumab alone also suggests it would be prudent to use 
natalizumab only as monotherapy at this time [237].  
Assessment of blood samples for the presence of anti-JCV antibodies has been 
evaluated as another means to identify MS patients at risk of developing PML 
because JCV infection is required for PML occurrence. JCV specific antibodies can 
be measured using different assays. Gorelik and colleagues from Biogen Idec 
developed a 2-step virus-like particle-based enzyme-linked immunosorbent assay 
(ELISA) (STRATIFY JC virus, 2-step anti-JC virus antibody assay, Biogen Idec, 
Cambridge, MA) using recombinant VP1 protein to detect JCV specific antibodies, 
combined with a secondary confirmatory ELISA [239]. This test, which identified 
54% of 800 MS patients treated with natalizumab in STRATA study (Safety of 
Tysabri, redosing and treatment) as seropositive with a 2% annual seroconversion 
rate, has a false negative rate of 2.5% [238]. In addition, blood from 17 patients 
who subsequently developed PML were all seropositive when tested with this 
assay 16-180 months after PML onset, suggesting that seropositivity at baseline is 
a significant predictive risk factor for PML development. 
PML incidence was estimated for seropositive and seronegative patients using the 
overall PML incidence and anti-JCV antibody prevalence rates for the general MS 
population (55%) and for the natalizumab-treated PML patients who had pre-PML 
samples tested for anti-JCV antibodies before PML diagnosis (100%). The 
incidence of PML in anti-JCV antibody-negative patients and the relative risk of 
PML between anti-JCV-antibody-positive and negative patients were estimated 
with sensitivity analysis. In anti-JCV antibody-positive patients, the incidence of 
PML was estimated to be approximately 2-fold greater than the incidence of the 
overall natalizumab-treated population. In anti-JCV antibody-negative patients, 
PML incidence was estimated at 0 cases per 1,000 patients, because no PML 
patients tested negative for anti-JCV antibodies. Therefore, one hypothetical case 
of PML was assumed to develop in a patient who tested negative for anti-JCV 
antibodies, as a part of the sensitivity analysis. 
On the basis of this hypothetical case, the estimated incidence of PML in anti-JCV 
antibody-negative patients would be 0.11 cases per 1,000 patients, or at least 20-
fold lower than the incidence in anti-JCV antibody-positive patients [239]. 
So, the estimated incidence of PML in anti-JCV antibody-positive patients resulted 
significantly (p<0.0001) greater compared with anti-JCV antibody-negative 
patients. This analysis supports the importance of the use of anti-JCV antibody-
serostatus as a risk stratification tool for development of PML. 
1.3.2 Quantification of PML risk according to risk factors 
Recently, Bloomgren and colleagues developed a risk-factor algorithm to estimate 
the incidence of PML among patients with and without the established risk factors 
for natalizumab-associated PML using data from postmarketing sources, clinical 
studies, and an independent Swedish registry [224]. This algorithm is based on the 
data of PML risk according to anti-JCV antibodies (positive or negative), prior use 
of immunosuppressant (yes or no), and duration of natalizumab treatment (1 to 24 
months versus 25 to 48 months).  
They determined the number of PML cases among patients who had received 1 to 
24 months of natalizumab treatment or at least 25 to 48 months of Natalizumab 
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treatment, stratified according to status with respect to prior use of 
immunosuppressants. Then, considering two risk-factors, they estimated the 
incidence of PML among patients who were positive for anti-JCV antibodies by 
dividing the number of patients with natalizumab-associated PML who were 
positive for anti-JCV antibodies by estimated number of natalizumab-treated 
patients who were positive for anti-JCV antibodies in the postmarketing setting 
[224] (fig. 17). 
Since exposure to JCV is fundamental for the development of PML, patients who 
were negative for anti-JCV antibodies represent the subgroup at the lowest risk in 
the PML risk-stratification algorithm, with an estimated incidence of 0.09 cases or 
fewer per 1,000 patients. In the highest-risk subgroup (patients who have all the 
three risk-factors), the estimated incidence of PML was approximately 11.1 cases 
per 1,000 patients [224,240].  
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Fig. 17: approximate incidence of PML, stratified according to risk factors (from 
[224]) calculated through February, 2012). Estimates of the incidence of PML are 
shown, stratified according to prior or no prior use of immunosuppressants and 
duration of natalizumab treatment (Panel A) and according to positive or negative 
status with respect to anti-JC virus antibodies, prior or no prior use of 
immunosuppressants, and duration of natalizumab treatment (Panel B). 
 
1.3.3 Management of PML risk 
For patients with MS who are considering or receiving natalizumab therapy, the risk 
of PML can be stratified according to positive or negative status with respect to 
anti-JCV antibodies, prior or no prior use of immunosuppressants, and the duration 
of natalizumab treatment. This may help in the identification of patients for whom 
natalizumab therapy is most appropriate and may reduce the incidence of PML, a 
serious potential complication of the therapy. 
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Nevertheless, clinical vigilance for the clinical features of PML remains of critical 
importance for PML risk management strategy. All patients undergoing 
natalizumab therapy must have a baseline MRI scan within 3 months before 
starting treatment, and annually during the therapy. Moreover, all anti-JCV 
antibody-negative patients may potentially be treated with minimal risk, but it is 
currently recommended that negative anti-JCV antibody status should be re-
evaluated on a six-month basis. Once a patients tests positive for anti-JCV 
antibodies, he should be considered exposed to the virus, with regards to risk 
stratification, and no further testing is recommended. On suspicion of PML, 
natalizumab should be stopped, and MRI and CSF examination undertaken (fig. 
18). 
 
 
 
 
 
Fig. 18: algorithm for diagnosis and treatment of natalizumab-associated PML. 
 
 
1.3.4 Identification of markers for natalizumab-associated PML 
development and related studies 
A laboratory marker that predicts the likelihood of PML development is required for 
selection of people most likely to benefit safely from natalizumab treatment and for 
early detection of PML. 
Because PML is caused by JCV, and detection of JCV is a strong indicator of viral 
presence, the presence of JCV DNA in peripheral body fluids may be useful for 
stratification of PML risk. Nevertheless, there is no convincing evidence that 
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monitoring JCV replication in either blood (plasma or PBMCs), urine or CSF 
provides useful information about the risk of developing PML. 
Chen and colleagues [229] has suggested that subclinical reactivation of JCV 
occurs frequently in natalizumab treated patients and that JCV shedding, identified 
in urine samples, is associated with a transient drop in the JCV-specific cellular 
immune response. In particular, they followed 19 patients with RR-MS, enrolled in 
the study before they started natalizumab treatment over an 18-month period. 
Blood and urine samples were collected before starting the therapy and then at 3, 
6, 9, 12, and 18 months, at the time of their natalizumab infusion. Quantitative real-
time polymerase chain reaction (Q-PCR) was used for the detection of JCV DNA. 
They showed an increase in the frequency of JCV excretion in the urine, which was 
detected in 63% of the 19 patients after 12 months of natalizumab therapy, and a 
detection of viremia in 60% of the patients tested at 18 months. 
This has not been replicated in larger studies [240-243], as in the analysis 
performed on urine and blood samples from 1,400 individuals participating in 
clinical studies on natalizumab, in order to determine if the presence of JCV DNA 
could be useful in predicting PML risk in natalizumab-treated MS patients [241]. 
Using Q-PCR it was reported that viremia was rare, treatment with natalizumab 
was not associated with an increased prevalence of JCV viremia at the time points 
that samples were taken, the presence of JCV DNA in the blood was not 
associated with the development of PML, and patients who developed 
natalizumab-related PML tested negative in blood and PBMCs prior to the onset of 
sympthoms [241]. 
Another study from Sadiq and colleagues reported the detection of JCV DNA by 
PCR in the CSF of 8/200 MS patients receiving natalizumab. Subsequent PCR in 
these 8 patients was negative after stopping natalizumab. None of the patients in 
this study developed PML [244]. 
Thus, there is no evidence that, using currently available methods, testing for JCV 
DNA in biological fluids is useful for predicting DNA development. In contrast, 
serological assessment of anti-JCV antibody status may offer a more sensitive and 
practical means of identifying patients who may be infected by JCV. 
However, a recent study from Laroni and colleagues has evaluated the utility of 
testing JCV DNA, together with anti-JCV antibodies, in biological samples of 
natalizumab-treated patients, as a tool for PML risk stratification [245]. 126 subjects 
were enrolled in this study and a cross-sectional study was performed on 63 
patients testing JCV-DNA in blood, PBMCs, and urine. The presence of JCV-DNA 
was assessed longitudinally in a cohort of 33 subjects, one of which developed 
PML, and serum samples from another patients who developed PML was tested 
retrospectively. Anti-JCV antibodies and urinary JCV-DNA were both tested in 73 
patients. The cross-sectional and longitudinal studies reported that no reactivation 
of JCV DNA in urine or other biological samples occurs during natalizumab 
treatment. The patient who developed PML during the longitudinal study was 
constantly positive for JCV DNA in urine samples since before starting the therapy. 
This observation supports the hypothesis that PML in natalizumab-treated patients 
is likely to be a reactivation of a precedent infection, rather than a first infection. 
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Regarding the analysis on the correlation between urinary JCV DNA and anti-JCV 
antibodies, the anti-JCV antibodies test confirmed its higher sensibility (52% 
positive patients) compared to urinary JCV DNA (42.5%), with a false negative rate 
of about 2.5%, probably due to an inter-individual difference in the immune 
response to JCV infections. The authors of this work have concluded that testing 
JCV DNA in serum, whole blood or PBMCs has no clinical utility, while testing 
urinary JCV DNA allows identifying patients who harbor the JCV. Thus, this could 
be useful for identifying individuals at risk of PML among those who resulted 
negative at anti-JCV antibodies test. 
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2. Aim of the study 
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MS is a complex chronic immune mediated disease of the CNS. Its etiology is 
currently unknown and its pathogenesis is only partially understood. Complex 
genetic traits as well as environmental factors determine the susceptibility to 
develop the disease and also immune mechanisms play an essential role in driving 
the disease process.  
In addition to the immunomodulatory therapies approved for MS, mAbs have 
emerged as promising treatments to reduce the symptoms of MS. In particular, the 
humanized mAb natalizumab binds and block the α4 integrin, preventing the 
binding of T-lymphocytes to the adhesion molecules VCAM-1 on endothelial cells, 
their migration across the BBB and the consequent inflammation. Although its 
proven efficacy in RR-MS treatment, natalizumab therapy results in reduced 
immune surveillance of the CNS that predisposes to the reactivation of latent 
viruses, such as JCV, the etiologic agent of PML. 
By October 2012, a total of 298 cases of PML have been reported for 108,300 
natalizumab-treated MS patients. Sixthy-three out of 298 died, representing a 
death rate of 21%. 
The main aim of this work is to better understand the molecular basis of 
demyelinating diseases, by studying the association between natalizumab therapy, 
JCV reactivation and PML, and to identify possible biomarkers associated with an 
elevated risk of developing PML in natalizumab-treated MS patients, in order to 
further stratify patients at risk. In addition, herpes viruses Epstein-Barr (EBV), 
Varicella Zoster (VZV), Human Cytomegalovirus (HCMV), Herpes Simplex-1 (HSV-
1) and Human Herpes Virus-6 (HHV-6) have been searched to evaluate if they 
could be involved in demyelinating diseases pathogenesis. These objectives have 
been achieved through an extensive longitudinal study involving three different 
demyelinating diseases: MS, PML and NDLE, a PML-like leukoencephalopathy, 
which occurs in the absence of the JCV genome in the CSF. 
A total of 121 patients was enrolled in this study and their biological fluids collected 
at various stages of the diseases, in order to evaluate JCV reactivation/replication 
and its relation with natalizumab treatment and PML risk. 
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3. Materials and Methods 
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3.1 Biological samples  
CSF, peripheral blood (PB), serum and urine samples were collected, processed 
and freezed until the time of use. 
In particular, CSF and urine samples were aliquoted and stored at -80°C until the 
time of DNA extraction, while PB samples were taken in sterile tubes containing the 
anticoagulant ethylenediaminetetraacetic acid (EDTA), aliquoted, and stored at 4°C 
until the time of DNA extraction, than at -80°C. 
Sera samples were collected in tubes containing an inert barrier gel that is present 
in the bottom of the tube. The samples were centrifuged at 3000 rpm for 10 
minutes, and during this time the barrier gel moves upward to the serum-clot 
interface, where it forms a stable barrier separating the serum from fibrin and cells. 
The serum is then aliquoted and stored at -80°C before the DNA extraction. 
3.2 DNA extraction 
DNA extraction from biological samples has been carried out with commercial kits, 
following the manufacturer instructions. 
In particular, the general principles of the protocols are lysis buffers, that 
destabilizes the cell membranes, leading to the breakdown of cellular structure. 
The addition of a chaotropic salt during or after cell lysis, disrupts the protein 
structure by interfering with hydrogen bonding, Van der Waals interactions, and the 
hydrophobic interactions. Cellular proteins are largely insoluble in the presence of 
the chaotropic agent and can be removed by centrifugation or filtration. This DNA 
extraction methods are based on the binding properties of silica or glass particles. 
DNA will bind to silica particles with a high affinity in the presence of a chaotropic 
salt. After the other cellular components have been removed the DNA can be 
released from the silica/glass particles by suspending them in water. Without the 
chaotropic salt the DNA no longer binds to the silica/glass and is released into 
solution. 
3.2.1 DNA extraction from CSF, urine and serum samples 
Viral DNA extraction from CSF, urine and serum samples is performed with 
NucleoSpin RNA Virus kit (Macherey Nagel, Germany), which can be applied to 
acellular bodily fluids. With this commercial kit, viruses are lysed quickly and 
efficiently by Lysis Buffer RAV1 which is a highly concentrated solution of 
guanidinium thiocyanate. DNA viruses are usually difficult to lyse and require 
Proteinase K digestion. Lysis buffer and ethanol create appropriate conditions for 
binding of nucleic acids to the silica membrane of the columns.  
Contaminations (potential PCR inhibitors) like salts, metabolites and soluble 
macromolecular cellular components are removed in simple washing steps with 
ethanolic buffers RAW and RAV3. The nucleic acids can be eluted in water and are 
ready-for-use in subsequent reactions. 
In particular, the exact procedure for viral DNA extraction from urine and sera 
samples is based on the addition of 600 µl lysis buffer RAV1 to 150 µl of the 
sample and 20 µl of proteinase K solution (20 mg/ml stock solution). The mixture is 
incubated for 5 minutes (min) at 70°C for sample lysis. Then, 600 µl ethanol (96–
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100 %) are added to the clear lysis solution and the lysed sample is loaded in the 
columns and centrifuged for 1 min at 8,000 x g. Two washing steps are carried out 
with 500 µl of buffer RAW and 600 µl of buffer RAV3, separated by centrifugation 
for 1 min at 8,000 x g. This washing step removes contaminants and PCR 
inhibitors. The third washing step is performed adding 200 µL buffer RAV3, and 
centrifuging for 4 min at 11,000 x g to remove ethanolic buffer RAV3 completely. 
Since residual buffer RAV3 may inhibit subsequent reactions which are extremely 
ethanol-sensitive, the column is incubated for 1 min at 70°C to remove any 
remaining traces of ethanol. To elute viral DNA, 50 µl RNase-free H2O (preheated 
to 70°C) is added and the column is incubate for 2 min at 70°C, and then 
centrifuged for 1 min at 11,000 x g. 
3.2.2 DNA extraction from PB samples 
The QIAamp DNA Blood Mini Kit (Qiagen, USA) simplifies isolation of DNA from 
blood with fast spin-column. DNA binds specifically to the QIAamp silica-gel 
membrane while contaminants pass through. PCR inhibitors such as divalent 
cations and proteins are completely removed in two efficient wash steps, leaving 
pure nucleic acid to be eluted in water.  
The procedure is based on the addition of 40 µl of Qiagen protease (for 
proteolysis) to 400 µl of whole blood and 400 µl of lysis buffer AL. The mixture is 
incubated at 56°C for 10 min. Then, after the addition of 400 µl of ethanol (96-
100%), the mixture is applied on the QIAamp mini spin column and centrifuged for 
1 min at 6,000 x g, in order to allow DNA adsorption onto the silica membrane. 
DNA bound to the membrane is washed in two centrifugations, and the use of two 
different wash buffers, buffer AW1 and buffer AW2, significantly improves the purity 
of the eluted DNA. In addition, wash conditions ensure complete removal of 
residual contaminants without affecting DNA binding. The washing steps are 
achieved with 500 µl buffer AW1, followed by a centrifugation for 1 min at 6,000 x 
g, and 500 µl buffer AW2, followed by a centrifugation for 3 min at full speed 
(20,000 x g). Further centrifuge at full speed for 1 minute helps to eliminate the 
chance of residual buffer AW2. For DNA elution, 50 µl distilled water are added to 
the column, which is then incubated at room temperature for 5 min for yields 
improvement, and centrifuged at 6000 x g for 1 min. 
Thus, the concentration of the eluted DNA is quantified at a wave length of 260 nm 
by means of a spectrophotometric analysis with the SmartSpec Plus 
Spectrophotometer (Bio-Rad), using a 50-fold dilution. 
3.2.3 RNA extraction from CSF samples 
HIV-1 RNA is purified from CSF samples by means of QIAamp viral RNA mini kit. 
The sample is first lysed under highly denaturing conditions to inactivate RNases 
and to ensure isolation of intact viral RNA. Buffering conditions are then adjusted to 
provide optimum binding of the RNA to the membrane, and the sample is loaded 
onto the column. The RNA binds to the membrane, and contaminants are 
efficiently washed away in two steps using two different wash buffers. High-quality 
RNA is eluted in water. The exact procedure is based on the addition of 560 µl of 
lysis buffer AVL containing carrier RNA to 140 µl of CSF. After an incubation at 
room temperature for 10 min to allow the lysis of viral particles, the mixture is 
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added of 560 µl of ethanol (96-100%). This mixture is applied to the column, which 
is centrifuged for 1 minute at 6,000 x g. The membrane in the column is washed 
with 500 µl of buffer AW1, with a centrifugation for 1 min at 6,000 g. The second 
washing is performed with 500 µl of buffer AW2 and is followed by a centrifugation 
for 3 min at 20,000 g (full speed). To eliminate any chance of possible buffer AW2 
carryover, the column is further centrifuged for 1 min at full speed. Viral RNA is 
eluted in 50 µl of RNase-free water, after incubation at room temperature for 1 min 
and a centrifugation for 1 min at 6,000 x g. 
3.3 Quantitative Real-Time PCR 
Real-Time PCR, also called quantitative PCR (Q-PCR), is one of the most powerful 
and sensitive gene analysis techniques available and is used for a broad range of 
applications including quantitative gene expression analysis, genotyping, SNP 
analysis, pathogen detection, drug target validation and for measuring RNA 
interference. Since, it measures PCR amplification as it occurs, it represents an 
evolution of the traditional standard PCR, in which results are collected after the 
reaction is complete, making it impossible to determine the starting concentration 
of nucleic acid. 
In particular, Q-PCR systems use fluorescent reporter dyes to combine DNA 
amplification and detection steps in a single tube format, and measure products 
generated during each cycle of the PCR process, which are directly proportional to 
the amount of template prior to the start of the PCR itself. Regarding the 
fluorescent reporter, its signal increases in direct proportion to the amount of PCR 
product. 
The Q-PCR assays of this study were performed using the TaqMan chemistry, 
based on fluorogenic-labeled probes that use the 5’ nuclease activity of Taq DNA 
polymerase, the absolute quantitation method, and the 7500 RealTime PCR 
System (Applied Biosystem, USA). 
3.3.1 Q-PCR for HIV-1 
To detect the presence of HIV-1 genome in the CSF, a Q-PCR targeting the gag 
gene was performed using primers and probe shown in tables 4 and 5. The probe 
was labeled at the 5’ end with the reporter dye FAM and at the 3’ end with the 
quencher dye MinorGrooveBinder (MGB). The standard curve was obtained using 
the OptiQuant HIV-1 RNA Quantification panel (Acrometrix, USA), containing 
seven members, one of which was the negative. Each panel member contained 
HIV-1 viral RNA at a predetermined level and in particular intact and incapsidated 
viral particles which have been subjected to an extraction step for viral RNA 
releasing. The positive panel members were produced by making quantitative 
dilutions. 
The limit of detection of this assay was 1 copy/reaction. 
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Table 4: probe used in the Q-PCR assay for HIV-1. 
 
PROBE POSITION SEQUENCE 
HIVprobeMGB 488-507 
5‘- 6-FAM- TGT TAA 
AAG AGA CCA TCA AT- 
MGB- 3‘ 
 
 
Table 5: primers used in the Q-PCR assay for HIV-1. 
 
PRIMER POSITION SEQUENCE 
HIVMGBF 467-486 5’- GAC ACT  AAG CAG CCA TGC AA -3‘ 
HIVMGBR 509-531 5’- CTA TCC CAT TCT GCA GCT TCC T -3‘ 
 
 
The assay is performed using The TaqMan One-Step RT-PCR Master Mix 
Reagents Kit (Applied Biosystems, USA), which is designed for the reverse 
transcription (RT) and PCR amplification of a specific target RNA from either total 
RNA or mRNA. One-step RT-PCR performs RT as well as PCR in a single buffer 
system without interruption.  
 
The reaction mix was prepared as follows: 
− Taqman Universal PCR Master Mix (2X)                                     25 µl 
− MultiScribe (40X) and RNase inhibitor mix                               1.25 µl       
− HIVMGBF (0.9 µM)                                                                     0.7 µl 
− HIVMGBR (0.9 µM)                                                                     0.7 µl 
− HIVprobeMGB (0.2 µM)                                                              0.1 µl 
− Template RNA                                                                              10 µl 
− H2O                                                                                     up to 50 µl 
 
The thermal cycling parameters are the following: 
 
 RT AmpliTaq Gold 
activation PCR 
 
Hold Hold 
Cycles (40 cycles) 
Denature Anneal/extend 
Time 30 min 10 min 15 1 min 
Temperature 48°C 95°C 95°C 60°C 
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3.3.2 Q-PCR for JCV 
The Q-PCR protocol for the detection of JCV DNA in CSF, urine, PB and sera 
samples has been already described elsewhere [246]. The test sensitivity was 2 
copies/reaction. 
The standard curve for JCV assay was constructed with ten-fold serial dilutions 
(range: 1.1x104 to 1,1x10 plasmid copies/µl) of a plasmid containing the entire JCV 
genome, MAD1 strain (Advanced Biotechnologies, USA). 
Primers and probe for this assay, targeting the T-Ag region, are described in table 
6 and 7: 
 
 
Table 6: probe used in the Q-PCR assay for JCV. 
 
PROBE POSITION SEQUENCE 
JCV Probe 4323-4350 
5‘- 6-FAM- TCA TCA 
CTG GCA AAC ATT TCT 
TCA TGG C-TAMRA -3‘ 
 
 
Table 7: primers used in the Q-PCR assay for JCV. 
 
PRIMER POSITION SEQUENCE 
JCV Forward 4299-4321 5’- GAG TGT TGG GAT CCT GTG TTT TC -3‘ 
JCV Reverse 4352-4375 5’- GAG AAG TGG GAT GAA GAC CTG TTT -3‘ 
 
 
The reaction mix was prepared as follows: 
− Maxima probe qPCR Master Mix (2x) (M Medical)                   12.5 µl 
− JCV Forward (0.4 µM)                                                               0.12 µl 
− JCV Reverse (0.4 µM)                                                              0.12 µl 
− JCV Probe (0.2 µM)                                                                  0.05 µl 
− Template DNA                                                                                5 µl 
− H2O                                                                                     up to 25 µl 
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The thermal cycling parameters are the following: 
 
 Incubation AmpliTaq Gold 
activation PCR 
 
  
Cycles (40 cycles) 
Denature Anneal/extend 
Time 2 min 10 min 15 1 min 
Temperature 50°C 95°C 92°C 60°C 
 
 
3.3.3 Q-PCR for herpes viruses 
Q-PCR assays were performed for the detection of herpes viruses EBV, VZV, 
CMV, HSV-1 and HHV-6, using primers and probes described in the table 8 and 9: 
 
 
Table 8: probe used in the Q-PCR assay for Herpes viruses. 
 
 PROBE POSITION SEQUENCE 
EBV EBV Probe Unknown Sequence proprietary (Applied Biosystem, USA) 
VZV VZV Probe 58286-58307 
5‘- 6-FAM- ACC AGA 
TCC CGA CGA AGC 
GTG C-MGB -3‘ 
HCMV CMV Probe Unknown Sequence proprietary (Applied Biosystem, USA) 
HSV-1 HSV1 Probe Unknown Sequence proprietary (Applied Biosystem, USA) 
HHV-6 HHV6 Probe Unknown Sequence proprietary (Applied Biosystem, USA) 
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Table 9: primers used in the Q-PCR assay for Herpes viruses. 
 
 PRIMER POSITION SEQUENCE 
EBV 
EBV Forward Unknown Sequence proprietary (Applied Biosystem, USA) EBV Reverse 
VZV 
VZV Forward 58264-58284 5‘- ACA AAA ACA CCC GAC TCG AAA -3‘ 
VZV Reverse 58309-58330 5’- TCT ATT GGC ACG CAA CTC AAC T -3’ 
HCMV CMV Forward Unknown Sequence proprietary (Applied Biosystem, USA) CMV Reverse 
HSV-1 HSV1 Forward Unknown Sequence proprietary (Applied Biosystem, USA) HSV1 Reverse 
HHV-6 
HHV6 Forward Unknown Sequence proprietary (Applied Biosystem, USA) HHV6 Reverse 
 
 
The reaction mixes were prepared as follows: 
− Maxima probe qPCR Master Mix (2x) (M Medical)                   12.5 µl 
− Primer Forward (0.4 µM/ 0.9 µM only for HHV-6)        0.12 µl/ 0.27 µl 
− Primer Reverse (0.4 µM/ 0.2 µM only for HHV-6)        0.12 µl/ 0.06 µl 
− Probe (0.2 µM)                                                                          0.05 µl 
− Template DNA                                                                                5 µl 
− H2O                                                                                     up to 25 µl 
 
The thermal cycling parameters are the following: 
 
 Incubation AmpliTaq Gold 
activation PCR 
 
  
Cycles (40 cycles) 
Denature Anneal/extend 
Time 2 min 10 min 15 1 min 
Temperature 50°C 95°C 92°C 60°C 
 
 
Stardard curves for the quantyification of the viral genomes were constructed using 
ten-fold serial dilutions of plasmids containing herpes viruses genome, and in 
particular: 
- EBV: B95-8 strain (dilution range: 1.2x104 to 1.2x10 copies/µl) 
- VZV: Rod strain (dilution range: 1.5x104 to 1.5x10 copies/µl) 
- HCMV: AD169 strain (dilution range: 1.6x104 to 1.6x10 copies/µl) 
- HSV-1: MacIntyre strain (dilution range: 1.4x104 to 1.4x10 copies/µl) 
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- HHV-6: GS strain (dilution range: 1.9x104 to 1.9x10 copies/µl) 
 
The viral copy concentration for all the Q-PCR assays was log-transformed and 
expressed as log [copies/CSF ml] for CSF, sera, and urine samples, and as log 
[copies/µg of isolated DNA] for the PB samples. 
3.4 Standard PCR 
PCR was applied to the molecular analysis of JCV strains amplified by Q-PCR in 
CSF and urine samples. All the amplifications were performed by using the 2720 
Termal Cycler (Applied Biosystem, USA). PCR products were then loaded on 
agarose gels and analyzed bt electrophoresis using Tris-Borate-EDTA (TBE) 
buffer. The DNA fragments were visualized with ethidium bromide (1µg/ml) under 
the UV light of the gelDoc-it Image System (UVP, USA). 
3.4.1 PCR for JCV VP1 gene 
For JCV genotyping, a 215 bp fragment of the JCV VP1 gene was amplified using 
a single set of primers, JLP15 (forward primer) and JLP16 (reverse primer) [247]. 
The exact primer sequences and the position on JCV genome are indicated in 
table 10: 
 
 
Table 10: probe used in the PCR assay for JCV VP1 gene. 
 
PRIMER POSITION SEQUENCE 
JLP15 1710-1734 5’-  ACA GTG TGG CCA GAA TTC CAC TAC C -3’ 
JLP16 1902-1924 5’- TAA AGC CTC CCC CCC AAC AGA AA -3’ 
 
 
The reaction mix was prepared as follows, using reagents from EuroClone, Italy:  
− 10X Buffer (without Mg2+)                                                               5 µl 
− dNTPs (10mM)                                                                               2 µl                       
− Mg2+ (50 mM)                                                                                 2 µl 
− JLP15 (10 pmol/µl)                                                                      1.5 µl 
− JLP16 (10 pmol/µl)                                                                      1.5 µl 
− EuroTaq DNA Polymerase (5U/µl)                                              0.4 µl           
− Template DNA                                                                                5 µl 
− H2O                                                                                     up to 50 µl 
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The amplification program is the following: 
 
STEP TIME TEMPERATURE NO. OF CYCLES 
Initial denaturation 9 min 94°C 1 
Denaturation 30 sec 94°C 
48 Annealing 30 sec 63°C 
Extension 30 sec 72°C 
Final extension 10 min 72°C 1 
 
 
3.4.2 Nested PCR for JCV TCR 
The analysis of the TCR region and its rearrangements was performed using a 
protocol, previously reported [246], for a nested PCR, which involves two sets of 
primers, used in two successive runs of PCR. The second pair of primers (nested 
primers) for the second PCR bind within the first PCR product and produce a 
second PCR product that is shorter than the first one. This approach has greater 
specificity than regular PCR, and it can yield detectable product, otherwise not 
visible in a simple PCR. 
Primers JRE1 and LP2 (outer) and RFOR and RREV (inner) are used to amplify a 
353 bp fragment belonging to the JCV TCR. 
The exact primer sequences and the position on JCV genome are indicated in 
table 11. 
 
 
Table 11: primers used in the PCR assay for JCV TCR. 
 
PRIMER POSITION SEQUENCE 
OUTER 
JRE1 4989-5009 5’- CCT CCC TAT TCA GCA CTT TGT -3’ 
LP2 518-537 5’- TGC GGC ACC CAT GAA CCT GA -3’ 
INNER 
RFOR 5085-5104 5’- CAG AAG CCT TAG CGT GAC AGC -3’ 
RREV 291-310 5’- GCC TCC ACG CCC TTA CTA CT -3’ 
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The reaction mix for the first amplification (outer) was prepared as follows, using 
reagents from EuroClone, Italy:  
− 10X Buffer (without Mg2+)                                                               5 µl 
− dNTPs (10mM)                                                                               2 µl                       
− Mg2+ (50 mM)                                                                                 2 µl 
− JRE1 (10 pmol/µl)                                                                          2 µl 
− LP2 (10 pmol/µl)                                                                             2 µl 
− EuroTaq DNA Polymerase (5U/µl)                                              0.4 µl           
− Template DNA                                                                                5 µl 
− H2O                                                                                      up to 50 µl 
  
The first amplification program, which yielded a 678 bp product, is the following: 
 
STEP TIME TEMPERATURE NO. OF CYCLES 
Initial denaturation 3 min 95°C 1 
Denaturation 30 sec 94°C 
30 Annealing 30 sec 59°C 
Extension 30 sec 72°C 
Final extension 7 min 72°C 1 
 
 
The reaction mix for the second amplification (inner) was prepared as follows, 
using reagents from EuroClone, Italy:  
− 10X Buffer (without Mg2+)                                                               5 µl 
− dNTPs (10mM)                                                                               2 µl                       
− Mg2+ (50 mM)                                                                                 2 µl 
− RFOR (10 pmol/µl)                                                                         2 µl 
− RREV (10 pmol/µl)                                                                         2 µl 
− EuroTaq DNA Polymerase (5U/µl)                                              0.4 µl        
− Outer amplified product                                                                  5 µl 
− H2O                                                                                      up to 50 µl 
 
The second amplification program, which yielded a 353 bp product inside the 
former, is the following: 
 
STEP TIME TEMPERATURE NO. OF CYCLES 
Initial denaturation 3 min 95°C 1 
Denaturation 30 sec 94°C 
30 Annealing 30 sec 63°C 
Extension 30 sec 72°C 
Final extension 7 min 72°C 1 
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3.5 DNA sequencing 
Each PCR fragment was sent to an external facility (Primm Srl, Italy) for the direct 
sequencing of both viral strands, on the basis of Sanger sequencing principles. 
Sequence homology searches were performed using a nucleotide BLAST search, 
database set “others”, from NCBI site (http://blast.ncbi.nlm.nih.gov/Blast.cgi), 
according to Agostini and colleagues [248] for JCV genotyping, and Ault and 
colleagues [249] and Jensen and Major [186] for JCV TCR rearrangements. 
3.6 Anti-JCV antibodies test 
All natalizumab-treated RR-MS pateints underwent the compulsory 2-step virus-like 
particle-based ELISA, used to detect anti-JCV antibodies in human sera and 
plasma. The assay incorporates an ELISA test and a supplemental confirmation 
test. The presence or absence of anti-JCV antibodies is determined 
spectrophotometrically at 450 nm. In the supplemetal confirmation test, soluble 
MAD-1 JCV virus-like particles (VLPs) were used to pre-adsorb antibodies against 
JCV prior to evuation of samples in the ELISA, in order to enhance binding of both 
low- and high-affinity antibodies specific for JCV, thereby increasing the sensitivity 
of the test. Results were calculated as percentage inhibition to determine 
decreases in reactivity in the ELISA after the samples were pre-adsorbed with JCV 
VLPs. Since this ELISA test is characterized by a false-negative rate of 2.5%, from 
March, 2012 it has been replaced by a second generation test, called STRATIFY 
JCV DxSelect test, characterized by an increased sensitivity.  
3.7 Statistical analysis 
Distribution data resulting from the Q-PCR analysis of all biological samples from 
the patients enrolled in this study were analyzed using the Student’s t-test. 
A chi-square test was used to analyze the statistical significance between a 
categorical outcome and a categorical determining variable. 
Only correlation with a p<0.05 were considered statistically significant. 
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4. Results 
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Results regarding the virological screening and molecular characterization of 
amplified JCV strain from PML and NDLE patients, which belong to a broadest 
study performed in our laboratory, are described in the section Results I. These 
data have been already reported in the literature, in the Journal of Cellular 
Physiology [250]. 
Results regarding the longitudinal study on natalizumab-treated RR-MS patients 
are shown in section Results II. 
4.1 Results I 
4.1.1 Case study 
From 2007, twenty-two HIV-1 positive (HIV-1+) patients with a confirmed molecular 
diagnosis of PML were recruited at the Infectious Diseases Department of San 
Matteo Hospital, Pavia and at the Neurological Department of the Mondino 
Institute, Pavia, for a longitudinal study.  
For these PML patients, on the basis of the presence/severity of symptoms at the 
onset and during the clinical course of the disease, three different groups were 
defined: 
1. 10 PML patients with a multisymptomatic onset , typical for PML, and a 
classical disease course, who died within one year after the time of the 
diagnosis (CPML); 
2. 9 PML patients who had a typical multisymptomatic onset, but a benign 
disease course (benign PML); 
3. 3 asymptomatic PML patients, showing brain lesions typical of PML at 
MRI, and JCV DNA in the CSF. 
CSF, PB and urine samples were collected at the time of the diagnosis and after 6 
months, when possible, to monitor the clinical course of the disease. The immune 
and virological features (CD4+ cells count and HIV-1 plasma viral load) were 
acquired for each patient from clinical recors.  
In addition, 6 HIV-1 negative patients with a confirmed molecular diagnosis of PML 
were included in this study, in order to analyse and compare the CSF JCV load and 
its molecular characterization at the time of the enrolment. 
These HIV-1 negative PML patients, who were not subjected to follow-up analysis, 
were affected with different form of haematological malignancy, in particular 4 
cases of chronic lymphocytic leukemia (CLL) and 2 cases of non-Hodgkin’s 
lymphoma. Two patients with CLL and one patients with non-Hodgkin’s lymphoma 
died within a few months from disease onset, two others are still alive, but with 
severe neurological conditions, and the remaining patient was unable to be 
contacted for follow-up. 
Twenty-two HIV-1+ patients with NDLE were also selected at the Clinic of 
Infectious Diseases, San Matteo Hospital, Pavia, and underwent virological 
analysis on CSF at the time of leukoencephalopathy diagnosis. 
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4.1.2 Demographic and virological features of PML patients at 
baseline 
The demographic and virological findings at baseline are shown in table 12. 
The twenty-two HIV-1+ PML patients included 21 males and 7 female, with a mean 
age of 42 years (range: 20-70 years) and all but one were on HAART therapy at 
the time of PML diagnosis. The mean baseline CD4+ cells count was 70.9±29.8/µl 
for the CPML patients, 220.2±78.4/µl for the benign PMl patients and 424±157.9/µl 
for the asymptomatic PML patients (CPML vs. benign and vs. asymptomatic PML: 
p<0.05) (fig. 19). The mean baseline HIV-1 load was log 4.3±4.1 copies/ml, log 
3.3±3.2 copies/ml and log 4.7±4.6 copies/ml for the CPML, benign PML and 
asymptomatic PML patients, respectively. 
At the time of the enrolment, the mean JCV load in the CSF determined by means 
of Q-PCR was log 6.0±1.2 copies/ml for the CPML patients, log 4.0±1.0 copies/ml 
for the benign PML patients, log 4.2±0.5 copies/ml for the asymptomatic PML 
patients, and log 5.8±1.3 copies/ml for the HIV-1 negative PML patients (CPML vs. 
benign PML: p<0.01; CPML vs. asymptomatic PML: p<0.05; HIV-1 negative vs. 
benign PML: p<0.01) (fig. 20). The mean HIV-1 RNA load in the CSF was log 
2.7±1.3 copies/ml for the CPML patients, log 2.2±1.0 copies/ml for the benign PML 
patients and log2.7±1.7 copies/ml for the asymptomatic PML patients. 
JCV DNA was detected from the PB in 4 of 7 samples from CPML patients (log 
3.15±1.1 copies/µg), in 1 of 7 samples from the benign PML patients and in none 
of the samples from the asymptomatic PML patients. JCV DNA was also amplified 
in 4 out of 7 urine samples from CPML patients (log 6.6±1.2 copies/ml), in none of 
the samples from the benign PML patients and in 1 sample from the asymptomatic 
PML patients. 
Regarding the herpes viruses analysis on PML CSF samples at baseline, no 
herpes virus genomes were amplified in PML patients. 
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Table 12: demographic and virological findings at baseline. 
 
 HIV-1+ PML PATIENTS 
HIV-1 
NEGATIVE PML 
PATIENTS 
 
CPML  
(10 
patients) 
BENIGN PML 
(9 patients) 
ASYMPTOMATIC 
PML (3 patients) 
HIV-1 
NEGATIVE PML 
(6 patients) 
Male/Female 9/1 5/4 3/0 5/1 
Mean CD4+ 
cells count 70.9±29.8/µl
a,b 220.2±78.4/µla 424±157.9/µlb n.a. 
Mean HIV-1 
viremia 
log 4.3±4.1 
copies/ml 
log 3.3±3.2 
copies/ml 
log 4.7±4.6 
copies/ml n.a. 
Mean CSF 
JCV load 
log 6.0±1.2 
copies/ml*,** 
log 4.0±1.0 
copies/ml*,*** 
log 4.2±0.5 
copies/ml** 
log 5.8±1.3 
copies/ml*** 
Mean CSF 
HIV-1 load 
log 2.7±1.3 
copies/ml 
log 2.2±1.0 
copies/ml 
log 2.7±1.7 
copies/ml n.a. 
JCV DNA  
in PB 
log 3.15±1.1 
copies/ml 
log 2.0 
copies/ml 0 n.a. 
JCV DNA  
in urine 
log 6.6±1.2 
copies/ml 0 log 5.3 copies/ml n.a. 
 
(aCPML vs. benign PML: p<0.05, bCPML vs. asymptomatic PML: p<0.05; *CPML vs. benign PML: 
p<0.01;** CPML vs. asymptomatic PML: p<0.05;*** HIV-1 negative vs. benign PML: p<0.01) 
 
 
 
 
 
Fig. 19: mean CD4+ cell count for HIV-1+ PML patients at baseline. 
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Fig. 20: mean JCV load in the CSF of PML patients at baseline. 
 
 
4.1.3 Virological features of PML patients during follow-up 
Follow-up was performed every six months, when possible, for virological analysis 
of collected biological samples. Follow up analysis was possible only for two CPML 
patients, six benign PML patients and all the three asymptomatic PML patients. In 
particular, the two CPML patients both had one follow-up examination six months 
after the enrolment, whereas the others CPML patients died within less than six 
months after PML diagnosis. The mean time of follow-up was 28 months (range: 6-
60 months) for the six patients from the benign PML group and 16 months (range: 
6-48 months) for the three patients in the asymptomatic PML group.  
As can be observed in table 13, 14 and 15, and in fig. 21, 22 and 23, the JCV load 
in the CSF determined by means of Q-PCR has increased in three patients, in 
comparison to the baseline level, while decreased in each of the other patients. 
Four patients demonstrated virological remission, which is the clearance of the 
virus from CSF. 
HIV-1 RNA was only detectable in the CSF samples from 3 PML patients during 
the follow-up, but all patients experienced the clearance of the virus during this 
period. 
During the follow-up, JCV load was monitored also in PB and urine for benign and 
asymptomatic PML patients. In the PB, JCV was repeatedly detectable in one 
patients, and 3 follow-ups, it was detectable in one out of ten consecutive samples 
from another patient and was not detectable in the other patients. Regarding the 
JCV Q-PCR analysis in the urine, viral DNA was amplified in two of 11 follow-up 
examinations in one patients and was repeatedly detected in one of the 
asymptomatic PML patients (from 5 follow-up). 
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Table 13: CSF JCV load (log[copies/ml]) during the follow-up in CPML patients. 
 
 Mean follow-up period: 6 months 
CPML T0 T1 
Patient#1 5.3 5.9 
Patient#2 6.11 5 
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Fig. 21: CSF JCV load (log[copies/ml]) during the follow-up in CPML patients. 
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Table 14: CSF JCV load (log[copies/ml]) during the follow-up in benign PML 
patients. 
 
 Mean follow-up period: 28 months (range: 6-60) 
Benign PML T0 T1 T2 T3 T4 T5 T6 
Patient#1 4.49 3.99 3.6     
Patient#2 6.32 5.27 3.23 3.23    
Patient#3 3.23 3.23 3.23 3.48 3.34 neg neg 
Patient#4 3.23 3.71 3.16 3.2 neg neg Neg 
Patient#5 3.23 5.09 5     
Patient#6 4.05 5.7      
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Fig. 22: CSF JCV load (log[copies/ml]) during the follow-up in benign PML patients. 
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Table 15: CSF JCV load (log[copies/ml]) during the follow-up in asymptomatic PML 
patients. 
 
 Mean follow-up period: 16 months (range 6-48) 
Asymptomatic PML T0 T1 T2 T3 T4 
Patient#1 3.9 3.5 3.5 3.2  
Patient#2 4.8 5.4 3.2 3.2 neg 
Patient#3 3.9 neg    
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Fig. 23: CSF JCV load (log[copies/ml]) during the follow-up in asymptomatic PML 
patients. 
 
 
 
Regarding the herpes viruses analysis on PML CSF samples during the follow-up 
period, no herpes virus genomes were amplified in PML patients. 
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4.1.4 Molecular characterization of JCV strains isolated from PML CSF 
The molecular analysis of JCV strains amplificated by Q-PCR was performed only 
in CSF samples and the results are shown in table 16. 
Eighteen CSF samples analyzed were identified as genotype 1, in particular 12 
genotype 1a and 6 genotype 1b. Seven samples contained genotype 2, 4 genotype 
2b and 3 genotype 2c. Finally, 1 sample contained genotype 4. There was not a 
significant difference in the distribution of these genotypes among PML patient 
group. 
 
 
Table 16: results of the molecular characterization of JCV strains isolated from 
PML CSF. 
 
 
CPML BENIGN PML ASYMPTOMATIC PML 
HIV-1 
NEGATIVE PML 
JC
V 
G
EN
O
TY
PE
 1a 4 5 2 1 
1b 2 1 1 2 
2b 2 1 1 / 
2c 1 / / 2 
4 / 1 / 1 
 
 
The molecular analysis of TCR rearrangements was performed for 25 CSF 
samples at baseline. Twenty-three out of 25 have shown a rearranged TCR 
structure, in particular 4 IR rearrangements and 19 IIR rearrangements, while 2 
samples from asymptomatic PML patients demonstrated an archetypal form, the 
IIS. The CPML patients and all but one of the HIV-1negative PML patients showed 
IIR rearrangements; one patient from the benign PMl group, one from the 
asymptomatic PML group and one from the HIV-1 negative PML group presented a 
Mad1 rearrangement, while one benign PML patient had a Mad4 rearrangement 
(Jensen and Major, 2001; Frisque et al., 1984). 
The same results were obtained from the analysis of JCV strains isolated from CSF 
during the follow-up. 
4.1.5 Demographic and virological features of NDLE patients 
Twenty-four patients with HIV-1 related leukoencephalopathy (NDLE) were 
enrolled in this study, 16 male and 8 female. Ten patients were completely 
asytmptomatic, while the remaining 14 presented symptoms milder than in PML. 
For these patients, CSF virological analysis was performed in order to identify the 
presence of JCV or other neurotropic virus. 
However, neither JCV nor human herpes virus genomes were amplified in the 24 
CSF of NDLE patients.  
78 
 
4.2 Results II 
4.2.1 Case study 
From January 2010, a total number of 48 subjects from the Multiple Sclerosis 
Center, Mondino Hospital, Pavia were included in this longitudinal study. All these 
patients were affected from the relapsing form of MS and were treated with 
natalizumab therapy, due to the failure, for an inadequate response to or for not 
toleration, of the first line disease-modifying MS treatment. 
Five out of 48 patients were lost during the follow-up period and thus excluded from 
the analysis of the results, because of reasons linked to natalizumab treatment, 
such as the onset of infectious complications and allergic reactions, or independent 
from the drug administration (as the end of the treatment). 
PB, serum and urine samples were collected from each patient at various time-
points during the treatment, in conjunction with monthly natalizumab infusion. 
Additionally, biological samples (PB, serum and urine) were collected once from an 
individual set of 25 MS individuals, enrolled as control group, affected from MS and 
not treated with natalizumab, but with a conventional immunosuppressive therapy, 
including Copaxone, Betaferon, Extavia, Avonex, Rebif or Azathioprine. These 
patients were treated from an average time of 2.5 years, ranging from 1 to 6 years. 
Demographics, treatment duration, and description of the collected samples from 
natalizumab-treated and control MS patients are summarized in table 17.   
The total number of natalizumab infusion for the natalizumab-treated patients was 
1,254, with mean treatment duration of 27.95 months (range 3-59). 
The biological samples were collected from natalizumab-treated patients for 741 
time-points, with a mean time-point for each patient equal to 16.75 (range 2-29). 
A total of 2,184 biological samples were collected from natalizumab-treated MS 
patients during the follow-up period, while 54 biological samples were collected 
from the reference group of control patients. 
The 43 natalizumab-treated patients enrolled were classified into two distinct 
subgroups, on the basis of the treatment duration at the time of the analysis: 
• Group A: 19 RR-MS patients, who underwent natalizumab infusion from 3 
to 24 months (M/F: 5/14; mean age: 35, range: 18-52); 
• Group B: 24 RR-MS patients, who underwent natalizumab infusion from 25 
to 59 months (M/F: 8/16; mean age: 40, range: 25-55). 
Demographics and treatment duration for Group A and Group B natalizumab-
treated patients are summarized in table 18.   
A total of 335 natalizumab monthly infusions have been performed for the patient 
of Group A, with a mean of 17.6 infusion (range 3-25) for each patient. The total 
number of time-points for Group A was 238, with an average of 12.5 (range 2-23). 
For patients of Group B, a total of 919 monthly infusions have been carried out, 
with a mean of 38.3 infusion (range 25-59). The total number of time-points for 
Group B was 503 and the average 21 (range 8-29). 
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Table 17: demographics, treatment duration, and description of the collected 
samples from natalizumab-treated and control MS patients. 
 
 Longitudinal Study 
 Natalizumab-treated 
patients Control group 
No. 43 28 
Mean Age (range) 37.5 (18-55) 43.1 (21-66) 
M/F 13/30 10/18 
Mean treatment 
duration at analysis 
in months (range) 
27.95 (3-59) 30 (12-72) 
Mean time-point 
(range) 16.75 (2-29) 1 
No. of samples 2,184 (766 PB, 761 serum, 657 urine) 
54 (18 PB, 21 serum, 15 
urine) 
 
 
 
 
Table 18: demographics and treatment duration for Group A and Group B 
natalizumab-treated patients. 
 
 Group A Group B 
Total patients 43 
No. 19 24 
Mean Age (range) 35 (18-42) 40 (25-55) 
M/F 5/14 8/16 
Mean treatment 
duration at analysis 
in months (range) 
17.6 (3-25) 38.3 (25-59) 
Mean time-point 
(range) 12.5 (2-23) 21 (8-29) 
 
 
4.2.2 Detection of JCV DNA in urine samples 
A Q-PCR assay for JCV is used to detect viral DNA in urine samples from 
natalizumab-treated RR-MS and control patients. 
Regarding the reference group, 7 out of 28 control patients (25%) are positive for 
JCV DNA in urine.  
Among natalizumab-treated patients, 22 out of 43 patients (51.2%) had at least 
one positive PCR in urine and 215 time-points out of 743 were positive for the 
presence of JCV DNA. 
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Fisher test was used to obtain the exact p value and to define if results regarding 
the differences on urine JCV positivity in natalizumab-treated patients and in 
controls were statistically significant. The calculated p value was p=0.0472. 
The mean JCV load in the urine of the control patients was log 6.2 copies/ml with a 
standard deviation of 1.5 (range: log 4.9- log 8.2 copies/ml), while the mean urine 
JCV load in natalizumab-treated group was log 7.2 copies/ml (standard deviation: 
1.6; range: log 3.1- log 10.9) (table 19). 
 
 
Table 19: results on the detection of JCV DNA in urine samples. 
 
 Natalizumab-
treated patients Control group p 
JCV+ patients/ 
total 22/43 7/28 0.0472 
JCV+ time-points/ 
total 215/743 - - 
Mean urine JCV 
load ± standard 
deviation (range) 
log 7.2 ± 1.6  
(log 3.1- log 10.9) 
log 6.2 ± 1.5  
(log 4.9- log 8.2) 0.1165 
 
 
In table 20 are shown results on JCV positivity in urine analyzed for each of the 
natalizumab-treated group, Group A and Group B. 
Regarding Group A, 9 patients out of 19 (47.4%) are at least once positive for the 
presence of JCV genome. JCV positive time-points are 67 out of 238 (28.15%). 
Group B positive patients were 13 out of 24 (54.2%), while 147 time-points out of 
503 were positive (29.2%). 
The mean JCV load for Group A was log 7.4 (range log 3.2- log 11) with a standard 
deviation of 1.7, and for Group B was log 7.2 (range log 3.15- log 7.8) with a 
standard deviation of 1.6. 
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Table 20: results on JCV positivity in urine analyzed for each of the natalizumab-
treated group, Group A and Group B. 
 
 Group A Group B p 
JCV+ patients/ 
total 9/19 13/24 0.7626 
JCV+ time-points/ 
total 67/238 147/503 0.7949 
Mean urine JCV 
load ± standard 
deviation (range) 
log 7.4 ± 1.7  
(range log 3.2- log 
11) 
log 7.2 ± 1.6  
(range log 3.15- 
log 7.8) 
0.1653 
 
 
4.2.3 Detection of JCV DNA in PB and serum samples 
JCV was not detectable in any of the serum available specimens, neither at 
baseline nor during the treatment. One natalizumab-treated patient had a positive 
blood sample (1/766 total PB samples) at 21st natalizumab infusion, with a low 
viral load equal to 46.8 copies/µg. At the same time-point JCV DNA was detected 
also in the urine. This patient had always JCV positive samples during the 
treatment.  
No PB samples from control patients were positive for JCV DNA. 
4.2.4 Trend of JCV load in urine during the treatment 
The total number of patients who were positive at baseline was 7/25 (28%). For 
further analysis, JCV positivity of RR-MS patients was classified during the first, 
second, third and fourth year of treatment (table 21 and fig. 24). 
Two out of 42 natalizumab-treated RR-MS patients became JCV-DNA positive 
during natalizumab therapy either for a reactivation or for a new viral infection, 
while 1 patient demonstrated the clearance of the virus. 
Six patients showed a sporadic reactivation of JCV in the urine, with viral detection 
in a maximum number of 3 time-points. 
Regarding the trend of JCV load during the treatment for each patient, the viral 
load unvaried in 6 patients. For 5 patients, it increased its value of about one 
logarithm, whereas for as many patients it decreased of about one logarithm. 
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Table 21: JCV positivity of RR-MS patients classified during the first, second, third 
and fourth year of treatment. 
 
Time of treatment JCV+ Patients Total patients % 
At baseline (T0) 7 25 28% 
At 6 months (T6) 9 24 37.5% 
At 9 months (T9) 9 24 37.5% 
At 12 months (T12) 10 21 47.6% 
At 18 months (T18) 11 27 40.1% 
At 24 months (T24) 13 27 48.1% 
At 30 months (T30) 7 22 31.8% 
At 36 months (T36) 4 14 28.6% 
At 42 months (T42) 3 15 20% 
At 45 months (T45) 2 10 20% 
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Fig. 24: trend of JCV load in urine during the treatment. 
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The trend of JCV load for each patient during the follow-up is represented in the 
following graphics. 
Representation of the unvaried JCV load for 6 patients: 
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Representation of the increased JCV load of about one logarithm: 
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Representation of the decreased JCV load of about one logarithm: 
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4.2.5 Molecular characterization of JCV strains isolated from urine 
samples 
The genotyping analyses of the VP1 region have shown a predominance of the 
genotype 1, detected in 15 JCV positive urine samples of natalizumab-treated RR-
MS patients. In particular, 9 urine samples were identified as genotype 1a and 7 as 
genotype 1b. Genotype 4 was identified in 3 JCV-positive urine samples; genotype 
2b and 2c were amplified in two samples each (table 22). 
Regarding the genotyping results of the control group, two urine samples contained 
genotype 1b, and two other samples were identified as genotype 1a and 4, 
respectively (table 22). 
JCV TCR organization was analyzed both in natalizumab-treated patients and in 
control patients, showing an archetypal form in all the considered samples (table 
22). 
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Table 22: results of the molecular characterization of JCV strains isolated from MS 
urine samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.6 Detection of herpes virus genomes in PB and serum samples 
The presence of herpes viruses EBV, VZV, HSV-1 and HHV-6 has been monitored 
in serum samples from natalizumab-treated patients and control patients. None of 
these viruses has ever been amplified in the available specimens. 
EBV genome has been searched also in PB samples by means of Q-PCR both at 
baseline and during the follow-up period, and it has been detected sporadically, 
with a percentage of EBV-positive PB samples equal to 22.2%. 
4.2.7 Serological reactivity to JCV 
The serological test STRATIFY has been performed for 38 out of 43 natalizumab-
treated RR-MS patients. Seventeen patients out of 38 (44.7%) have detectable 
anti-JCV antibodies in serum, whereas the remaining (55.2%) resulted negative at 
anti-JCV antibodies test. The latters underwent a re-test, one year from the first 
STRATIFY, and 12/16 patients already subjeted to the second test resulted 
negative at both test. 4/16 patients showed an anti-JCV antibodies positivity at the 
second ELISA test, while 5 out of 21 resulted negative at first STRATIFY must yet 
be tested for the second time. Regarding the twelve seronegative patients, 2/12 
has already been tested for the third time and has showed a negative result.   
JCV VP1 
Natalizumab-treated 
patients 
(Tot: 22 JCV+) 
Control Group 
(Tot: 7 JCV+) 
 Gen. 1a 9 1 
Gen. 1b 5 2 
Gen. 2b 2 0 
Gen. 2c 2 0 
Gen. 4 3 1 
JCV TCR 
Natalizumab-treated 
patients 
(Tot: 22 JCV+) 
Control Group 
(Tot: 7 JCV+) 
Archetype 22 5 
91 
 
The results on the correlation between urinary JCV-DNA and anti-JCV antibodies 
status determined at the first STRATIFY are showed in the table 23. 
 
Table 23: correlation between urinary JCV-DNA and anti-JCV antibodies status 
determined at the first STRATIFY test. 
 
 
 
 
 
Urinary JCV-DNA (+) 
(22) 
 
Urinary JCV-DNA (-) 
(21) 
Anti-JCV antibodies (+) 
(17) 
15 2 
Anti-JCV antibodies (-) 
(21) 
3 18 
 
 
As shown in the table, 15 out of 38 patients resulted postive both at urinary JCV 
DNA test and at anti-JCV antibodies test. Eighteen out of 38 resulted negative at 
both test. Three out of 22 natalizumab-treated patients with detectable JCV DNA in 
the urine resulted negative at anti-JCV antibodies test. This result represents a 
false-negative of the STRATIFY test, and it could demonstre the lower sensibility of 
ELISA test compared to Q-PCR. Finally, two patients showed positivity to anti-JCV 
antibodies in the absence of JCV DNA in the urine.  
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5. Discussion 
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Here a wide molecular and longitudinal study is presented aimed to give a 
significant contribution to the understanding of the molecular basis of 
demyelinating diseases pathogenesis.  
MS is a multifocal demyelinating disease with progressive neurodegeneration 
caused by an autoimmune response to self-antigens in genetically susceptible 
individuals. Patients often exhibit an initial clinically isolated syndrome, followed by 
a series of sub acute clinical events that spontaneously abate, referred to as a RR 
form of the pathology. At present, no cure exists for MS and the goals of treatment 
are to arresting or slowing the progression of disability, decreasing relapse rate, 
managing symptoms, and slowing subclinical disease progression. The most 
commonly used MS treatments are immunomodulating agents, such as IFNβ-1a, 
IFNβ-1b, GA and fingolimod. mAbs, which can target pathogenic pathways with 
higher specificity, higher potency and fewer adverse effects than other molecules, 
may have great potential as therapies for autoimmune diseases. Their 
development as treatments for MS is promising, mainly for patients failing classical 
immunomodulatory treatments, representing an important new treatment option. In 
particular, Natalizumab (Tysabri; Biogen-Idec, Elan Pharmaceuticals, USA), a 
humanized mAb directed against the α4 subunit of the adhesion molecule α4β1 
integrin, is the only mAb approved for the treatment of MS. Natalizumab reduces 
leukocytes ability to migrate across the BBB, and based on the results of two 
phase III clinical trials it was approved on November, 2004 for the treatment of 
highly active or rapidly evolving severe RR-MS. On February 2005, natalizumab 
was withdrawn voluntarily from the market after the occurrence of Progressive 
Multifocal Leukoencephalopathy (PML) in three patients, treated with the mAb in 
clinical trials for MS and Crohn’s disease, representing an incidence of 
approximately 1 case per 1,000 patients. Following the implementation of a risk 
management strategy, the US FDA and the EMA remarketed natalizumab as 
monotherapy for MS in July 2006, with recommendations for monitoring for new 
cases of PML. 
PML is an opportunistic demyelinating disease caused by JCV, most often in the 
context of immunodeficiency. PML remains an incurable and often fatal disease, 
although the wide use of antiretroviral treatment led to a significant reduction of 
mortality in HIV-1 positive PML patients from 90% to approximately 50% during the 
first three months of treatment, as a result of recovery of the immune system. 
However, the introduction of HAART was associated to the development of a PML-
like leukoencephalopathy, indicated as NDLE. This pathology is characterized by 
the presence of demyelinating lesions and mild symptoms resembling those of 
PML but in the absence of the JCV genome in the CSF. 
As of October 3, 2012 there have been 298 confirmed cases of PML among 
108,300 natalizumab-treated MS patients, with 63 deaths and a mortality rate of 
21.1%. Additionally, accumulated safety data from global risk management 
program, established at the time of natalizumab reintroduction on the market, have 
identified longer duration of natalizumab treatment, the use of 
immunosuppressants before the initiation of natalizumab therapy, and positive 
status with respect to anti–JCV antibodies, as assessed with the use of a two-step 
anti-JCV antibody assay (STRATIFY JCV, Focus Diagnostics), as risk factors for 
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PML [235,239,251]. The risk of PML was highest among MS patients who had all 
these three risk factors (positivity to anti-JCV antibodies, prior use of 
immunosuppressants, and natalizumab treatment for 25 to 48 months), with an 
estimated incidence of 11.1 cases per 1,000 patients. 
Although there are several differences between natalizumab-associated PML 
compared with PML in the contexts of immunodeficiency or malignancy, the 
common feature of demyelination has stimulated the research on the possible 
association between MS, JCV reactivation and PML. It is evident that there is still a 
need to identify markers for PML prognosis and diagnosis in natalizumab-treated 
MS patients, and a need for the definition of a screening test which can reliably and 
easily predict PML. 
To understand the mechanism of reactivation of a latent infection in natalizumab-
treated patients, its therapeutic principles of action must be considered. 
Natalizumab was specifically designed to reduce trafficking of lymphocytes into 
peripheral tissues; therefore, it was postulated that treatment with natalizumab 
results in reduced immune surveillance of the CNS. Two possible mechanisms of 
JCV reactivation are reported in the literature. Either the persisting virus within the 
CNS or passing virus during JC viremia is responsible for JCV reactivation in the 
setting of immunosuppression or impaired immunosurveillance [reviewed in 108]. 
In addition, since natalizumab forces hematopoietic stem cells and pre-B-cells  to 
migrate from the bone marrow, because of they cannot bind to vascular-adhesion 
molecules, patients with MS who receive natalizumab treatment have an increase 
in CD34+ cells in their circulation as well as an up-regulation of genes involved in 
B-cell maturation [252-254]. This dynamic creates a favorable environment for 
JCV, which can reside in a latent state in the bone marrow for long periods before 
the development of PML and which can use B-cells and their DNA-binding proteins 
to initiate viral replication. In fact, natalizumab up-regulates transcription factors 
important for the differentiation of B lymphocytes and, during natalizumab-induced 
B-cell differentiation, JCV-infected bone marrow cells might be activated, leading to 
JC viremia and PML as a consequence of natalizumab therapy. In this context, 
rearrangement of archetype JCV to PML-type could occur [255-257]. 
Since the presence of JCV DNA in body fluids is thought to represent active viral 
shedding or replication and since blood testing and urine analysis are less invasive 
than CSF testing, they are an attractive option to reveal some clues about JCV 
reactivation in MS patients. Previously published studies have reported conflicting 
information on the effect of natalizumab on JCV DNA presence in biological fluids 
[230,242,244,245]. 
Thus, to better understand the molecular basis of demyelination, and to identify 
possible risk factors for the development of opportunistic infections and early 
prognostic markers of infectious complication during natalizumab treatment of MS, 
a wide longitudinal study has been performed, based on the collection of biological 
fluids from MS patients subjected to natalizumab or other treatment, and from PML 
and NDLE patients. CSF, PB, urine and serum samples have been collected at 
various time-points and JCV genome searched, quantified and molecular 
characterized in order to monitor the viral presence and load, and to determine 
wheter they could be considered as risk factors for PML development. 
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Fifty patients with brain lesions and clinical symptoms suggestive of PML and 
NDLE have been enrolled in this study. CSF, urine and PB samples from these 
patients have been virologically evaluated, in order to monitor the presence of JCV 
and other neurotropic viruses both at baseline and during the follow-up. 
In particular, 22 HIV-1 positive PML patients were classified into three different 
groups on the basis of the symptomatology at the onset and during the progression 
of the disease at follow-up: 10 patients were included in the classical PML group, 9 
patients in the benign PML group and 3 patients in the asymptomatic PML group. 
Six HIV-1 negative PML patients, affected by onco-hematological malignancies, 
were also analyzed. Follow-up analysis were possible for only two CPML patients 
(mean follow-up period: 6 months), since eight patients died within few months, for 
six benign and the three asymptomatic patients (range of follow-up: 6-60 months), 
and for any of the HIV-1 negative PML patients. The analysis of immunological and 
virological features at baseline demonstrated that CPML patients had the lowest 
CD4+ cells count followed by the benign and the asymptomatic PML patients. The 
analysis of virological features performed at baseline by means of Q-PCR has 
shown that the mean JCV load in the CSF was significantly higher in the CPML 
group than in the other HIV-1 positive PML groups, and was very high also in the 
group of HIV-1 negative PML patients. These virological findings seem to suggest 
that factors related to both the JCV infection (high CSF viral load) and the host 
immune system (low CD4+ cell count) can influence the prognosis of the disease 
[reviewed in 250]. Additionally, they support previously published data, which 
reported a poor prognosis for HIV-1 negative PML patients. Indeed, of the HIV-1 
negative PML patients, three died within few months from disease onset, and two 
other are still alive, but with severe neurological conditions. 
JCV analysis during the follow-up has indicated that JCV load remained stable in 
two CPML patients, was decreased in four of the six benign PML patients and was 
decreased in all of the asymptomatic PML patients. The clearance of the virus from 
the CSF was evident in four cases. These data support previous findings reporting 
that the viral clearance occurs after 5 to 25 months of HAART and that a lowering 
of JCV replication in the brain is related to prolonged survival rate [258-259]. 
The slow progression of the disease that characterized the group of benign and 
asymptomatic PML patients was confirmed also by the clearance of HIV-1 RNA 
from the CSF. 
The viral strain amplified in CSF were molecular characterized by standard PCR, 
but no mutation or large change occurred in the viral genome organization neither 
at baseline nor during the follow-up. The genotyping analysis of VP1 region have 
shown a prevalence of genotype 1, confirming the geographical distribution of the 
viral strain, while the analysis of TCR rearrangements have shown a large majority 
of IR and IIR types, as expected. Nineteen of the IIR TCR were identified as 
different from all the other TCRs regarding sequence and length, and as unique in 
the NCBI database. Three JCV TCR sequences were found as Mad-1, the PML-
type strain, and one as Mad-4. The most interesting result, comes from the 
observation that the archetypal form IIS, usually isolated from urine of healthy and 
PML subjects and without an apparent infectious activity in vitro, was amplified 
from the CSF of two asymptomatic PML patients. The potential role of the different 
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molecular organizations of the JCV TCR in PML pathogenesis and in viral 
neurotropism has been long debated, and, to date, the rearranged forms of TCR 
seem to play a crucial role in PML pathogenesis [reviewed in 250]. 
On the basis of this finding, it is possible to assert tha the presence of a weaker 
promoter, such as the archetype, and the consequently low viral replication in the 
CNS of asymptomatic PML patients may partially explain the benign course of the 
disease. 
The detection of JCV DNA at baseline in PB and urine samples from PML patients 
did not show statistically significant results, and this is also for the analysis during 
the follow-up period. 
No herpes virus genomes were amplified in the CSF of PML patients, so these 
viruses seem not to be involved in PML pathogenesis. 
Twenty two HIV-1 positive patients affected by NDLE were enrolled and followed-
up, and it was confirmed that none of the searched neurotropic viruses was 
involved in the pathogenesis of this form of leukoencephalopathy, since neither 
JCV nor herpes viruses were found in the CSF from these patients. 
In order to investigate the role of JCV and other neurotropic viruses in PML onset 
during the natalizumab therapy in MS patients, seventy-six MS patients were 
recruited and PB, serum and urine were collected at the enrolment and monthly 
during the follow up to evaluate the viral presence. Forty-eight of these were 
affected by the RR form of the pathology and treated with the mAb natalizumab, 
while the others were enrolled as control group and have been treated from at least 
two years with the conventional disease-modifying therapy, such as INFβ, GA or 
azathioprine. 
Five of 48 RR-MS patients were dropped out from natalizumab therapy and from 
the analysis, because of the onset of complications not compatible with mAb 
treatment. The remaining 43 natalizumab-treated RR-MS patients were classified 
in two subgroups, in order to verify JCV replication within 24 months of therapy 
administration (time at which the PML risk is higher) and with the treatment 
continuation. 
No enrolled patients developed clinical or brain MRI evidence typical of PML. 
Q-PCR assay was performed to investigate JCV presence and viral load in PB, 
urine and sera collected at baseline and during the monthly time-points, 
concomitant to monthly infusion of the drug. 
Viral replication has been often detected in urine samples, while the viral genome 
was amplified only in one PB sample and no serum samples resulted positive for 
JCV. Comparing the findings in the case and the control groups, it seems that the 
virus replicates more in natalizumab-treated patients than in controls, but the 
urinary viral load remains comparable between the two groups. 
Regarding the comparison between the rate of JCV positivity among natalizumab-
treated patients and the time of treatment (number of monthly infusion), it appears 
that there is an increase of positivity until the 24th infusion/ month of treatment, and 
a decrease from the 36th infusion. This is in agreement with the findings of other 
reports, which describe a maximum risk for PML development during the first two 
years of natalizumab therapy [235,260,261]. A report by Chen et al. [230] suggests 
that the virus is shed in the urine in increasing amounts between 6 and 12 months 
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after natalizumab treatment begins, and this process may lead to viremia following 
treatment for 18 months. Sadiq et al. [245] reported that 3 of 200 patients had 
detectable JCV DNA. The JCV DNA detection in plasma occurred at the 6-month 
analysis, at 4 months of treatment for the second case, and the other JCV DNA 
case occurred after 18 months of natalizumab treatment. Jilek et al. did not show 
increased occurrence of JCV DNA in plasma, PBMCs, or urine in 24 patients 
treated with natalizuab for 18 months [244]. Rudick and colleagues analysed 
plasma, urine and PBMCs at baseline and after 48 weeks of natalizumab 
treatment, and their results did not confirm an induction of JCV DNA in body fluids 
[242]. 
It is important to underline that nobody have investigated the prevalence of urinary 
JCV DNA in urine of patients treated for more than 18 months, while this may be of 
great relevance, since most of PML cases occur after 2 years of treatment. 
All patients had undetectable herpes virus DNA both at baseline and at follow-up in 
the serum, while EBV genome was amplified occasionally in PB samples. Thus far, 
there are only a few reports on the reactivation of neurotropic latent virus other 
than JCV in natalizumab-treated patients. HHV-6 is a pleiotropic β-herpes virus 
commonly reactivated in the setting of acute and prolonged immunosuppression. 
HHV-6 has also been suggested to be associated with PML pathogenesis, and to 
be involved in the pathogenesis of MS, as well as EBV [reviewed in 108]. 
Nevertheless, on the basis of the results of this study, herpes viruses seem not to 
reactivate during natalizumab treatment. 
A comparison between the prevalence of urinary JCV DNA in natalizumab-treated 
patients and the serostatus with respect to anti-JCV antibodies has been 
performed, in order to evaluate the utility in testing JCV DNA togheter with anti-JCV 
antibodies in these patients as a tool for PML risk stratification. 
All MS patients subjected to natalizumab therapy compulsorily undergo the two-
step anti-JCV antibody assay STRATIFY, because seropositivity for anti-JCV 
antibodies, togheter with treatment duration >2 years and previous therapy with 
immunosuppressants, has been associated with an increased risk for PML 
development. This test is characterized by a false negative rate of 2.5%. In addition 
to obvious explanations for the false-negative results, such as sample mishandling, 
there are several biological explanations. First, the level of antibodies in the sample 
may be below the level of detection due to a very recent infection with the virus. 
Second, a low viral level may be present in the tested patients. Third, a false-
negative response may be due to the patient’s antibodies being directed to 
epitopes not represented in the MAD-1 JCV VLPs used in the assay. The most 
plausible explanation is an intrinsic variance among individuals in antibody 
response to JCV. 
Moreover, the false-negative rate, combined with the annual seroconversion rate 
(estimated as ~2% in the STRATA study) suggests that periodic retesting of 
seronegative patients is warranted in the clinical practice. 
This ELISA test has been performed for 38/43 natalizumab-treated MS patients 
enrolled in this study. 17/38 (44.7%) patients had JCV antibodies. The patients 
resulted regative at anti-JCV antibodies test were re-tested one year after, and 
16/21 patients already re-tested had not anti-JCV antibodies. Interestingly, a 
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seroconversion was shown for 4/16 (25%) patients, because they resulted positive, 
on the contrary to the first STRATIFY. This result may be due to a new infection 
with JCV in patients previously negative or, alternatively, could be proposed an 
explanation related to the test sensitivity. In fact, from March, 2012 the two-step 
ELISA assay developed by Gorelik and colleagues [239] characterized by a false-
negative rate of 2.5% has been replaced with an improved STRATIFY JCV assay, 
called STRATIFY DxSelect. This second generation test has an improved ability to 
detect seropositivity in samples with low levels of anti-JCV antibodies so that it 
should minimise the occurrence of false negative results. Biogen Idec anticipated 
that approximately 5-10% of MS patients with very low anti-JCV antibody levels 
who tested negative using first generation STRATIFY JCV test may test positive 
with STRATIFY DxSelect. As a result, there may be an increase in the number of 
MS patients who had previously tested anti-JCV antibody negative prior to March 
2012 and now test anti-JCV antibody positive at a rate above what might be 
expected from the scientific literature. Thus, it is expected that once MS patients 
have been tested with STRATIFY JCV DxSelect, the rate of changing serostatus 
stabilize. 
For the natalizumab-treated MS patients of this study, the anti-JCV antibodies 
evaluation has been performed with the first generation assay until March, 2012. 
Thus, the most recent test has been characterized by more sensitivity, which can 
explain the apparent seroconverion. So, it can be postulated that these 4 patients 
were JCV positive also at the time of the first test, but its lower sensitivity may have 
influenced the result, or that the seroconversion really happened. 
This result has a great clinical relevance, because patients with anti-JCV 
antibodies may have an increased risk to developed PML, in the presence of the 
other risk factors. It is fundamental that patients with negative anti-JCV antibodies 
are re-tested, at periodic intervals. 
Regarding the twelve patients seronegative also at the second test, 2/12 has 
already been tested for the third time and shown again negative results.   
Regarding the correlation between the urinary JCV DNA and anti-JCV antibodies, 
15 out of 38 (39.5%) tested patients were postive both at urinary JCV DNA test and 
at anti-JCV antibodies test. 18/38 (47.4%) resulted negative at both test. Three out 
of 22 natalizumab-treated patients with detectable JCV DNA in the urine resulted 
negative at anti-JCV antibodies test, both at the first test and at the re-test. This 
result represents a false-negative of the STRATIFY test, and it may be explained 
by the lower sensitivity of the ELISA test compared to the Q-PCR test, or 
alternatively by an inter-individual difference relative to the immune response to 
JCV infection. In these analyses, the anti-JCV antibodies test showed a false-
negative rate of 7.9% but an higher sensibility (44.7% positive patients) in 
comparison to urinary JCV DNA (40.8%). Finally, two patients showed positivity to 
anti-JCV antibodies in the absence of JCV DNA in the urine, probably due to an 
intermittent excretion of JCV DNA. In fact, when JCV establishes latency in the 
body, it is not shedded in the urine except in the case of reactivation or active viral 
replication. 
In conclusion, on the basis of the results of this longitudinal study on different 
demyelinating diseases it is possible to assert that, to date, the main markers of 
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prognosis of HIV-related PML seem to be the JCV load in the CSF determined at 
the time of the disease, a low CD4+ cell count at baseline (associated with a 
severe clinical course) and the TCR molecular organization, showing anomalous 
structure in the CSF of long-term survival patients. In addition, the clearance of 
JCV from the brain, also observed in long-term survival patients, is probably due to 
an improved immunological status. The same asserts can be sustained for PML 
associated to hematological malignancies, since the JCV load and the TCR 
molecular organization in HIV-1 negative patients correlated with the poor 
prognosis. 
This observation is alarming, because of the development of PML in HIV-1 
negative subjects is often related to the administration of new drugs, based on 
mAbs. Although JCV reactivation detected in urine from MS patients had a 
subclinical nature, the increase of viral replication during natalizumab treatment 
cannot be ignored and the constant monitoring of urinary JCV DNA allows 
identifying patients who harbor the virus and verifying if viral replication/shedding in 
the urine is really influenced by the treatment with the drug. Thus, testing urinary 
JCV DNA, together with anti-JCV antibodies, could be of particular utility for 
indentifying individuals at risk of PML, also among patients who resulted negative 
at anti-JCV antibodies test. The experience with natalizumab argues that directed 
investigation aimed at identifying biomarkers associated with an elevating risk for 
PML has a great importance, becoming the major challenge of the research in the 
near future. 
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